

CURRICULUM VITAE

KATHLEEN MIHO SAKAMOTO, M.D., Ph.D.

I. Personal Information

Shelagh Galligan Professor, Division of Hematology,
Oncology, Stem Cell Transplantation and Cancer Biology
Stanford University School of Medicine
Department of Pediatrics
CCSR Room 1215C
269 Campus Drive, Stanford, CA 94305-5162
Phone: (650) 725-7126, Fax (650) 725-7419
kmsakamo@stanford.edu

CITIZENSHIP United States

Educational Background

7/75-6/79	Williams College, Williamstown, MA; B.A. Cum Laude; Biology
7/81-6/85	University of Cincinnati, College of Medicine, Cincinnati, OH; M.D.
7/2000-1/2004	California Institute of Technology, Pasadena, CA; Ph.D. Biology Howard Hughes Medical Institute, Laboratory of Raymond J. Deshaies, Ph.D.

Postdoctoral Training

7/85-6/86	Internship, Pediatrics, Children's Hospital of Los Angeles
7/86-6/88	Residency, Pediatrics, Children's Hospital of Los Angeles
7/88-6/89	Fellowship, Hematology/Oncology, Children's Hospital of Los Angeles

Licensure

1986 California License, G58328
1994 DEA license, BS1361992

Board certification

1986 Diplomate, National Board of Medical Examiners
1989 Diplomate, American Board of Pediatrics (recertified 1999, 2006, 2016)
1994 Diplomate, American Board of Pediatrics, Hematology-Oncology (recertified 1999, 2006, 2016)

Research interests

Mechanisms of Leukemogenesis
Mechanisms of Bone Marrow Failure
Novel therapeutic approaches to treat cancer
Gene Regulation in Hematopoiesis

Research Experience

7/78-6/79	Senior Honors Thesis, Department of Biology, Williams College. "Effects of Centrifugation Time on Separation of Plant Organelles".

7/79-6/80	Research Assistant, Department of Biochemical Genetics, City of Hope Medical Center
7/93-6/96	Research Assistant, Department of Physiology, USC School of Medicine,
7/80-6/91	Postdoctoral Fellow, Division of Hematology-Oncology, in the laboratory of Judith C. Gasson, Ph.D., UCLA School of Medicine
7/99-6/09	Visiting Associate, laboratory of Raymond Deshaies, Ph.D., Department of Biology, California Institute of Technology, Pasadena, CA.
7/2000-12/03	STAR program/Graduate Studies, Division of Biology, Laboratory of Raymond Deshaies, PhD, Howard Hughes Medical Institute, California Institute of Technology, Pasadena, CA.

Professional Appointments

7/91-6/93	Clinical Instructor, Division of Hematology-Oncology, Department of Pediatrics, UCLA School of Medicine
7/93-6/94	Visiting Assistant Professor of Pediatrics, Division of Hematology-Oncology, Department of Pediatrics, UCLA School of Medicine
7/94-6/98	Assistant Professor of Pediatrics, Division of Hematology-Oncology, Department of Pediatrics, UCLA School of Medicine
7/95-11/2011	Joint appointment, Department of Pathology and Laboratory Medicine
7/98-6/2003	Associate Professor of Pediatrics and Pathology, Mattel Children's Hospital at UCLA, UCLA School of Medicine
7/2003-11/2011	Professor of Pediatrics and Pathology & Laboratory Medicine
7/04-6/09	Visiting Associate, Division of Biology, California Institute of Technology
7/2005-11/2011	Professor of Pediatrics and Pathology & Laboratory Medicine, David Geffen School of Medicine at UCLA
7/2005-11/2011	Division Chief, Hematology-Oncology, Mattel Children's Hospital, David Geffen School of Medicine at UCLA
7/2006-11/2011	Vice-Chair of Research, Mattel Children's Hospital, David Geffen School of Medicine at UCLA
7/2006-11/2011	Co-Associate Director of Signal Transduction Program Area, Jonsson Comprehensive Cancer Center
7/2008-7/2011	Pediatric Hematology/Oncology Fellowship Program Director, Mattel Children's Hospital UCLA
1/2011-10/2011	P.I., Children's Oncology Group at UCLA
6/2011-11/2011	Co-chair of the UCLA CTSI, Committee for Maternal, Child, Adolescent Health.
2011-2014	Division Chief, Pediatric Hematology/Oncology/Stem Cell Transplant/Cancer Biology, Stanford University School of Medicine and Director, Bass Cancer Center, Lucile Packard Children's Hospital
2011-2013	Fellowship Program Director, Pediatric Hematology/Oncology, Stanford University School of Medicine
2011-2014	Stanford Cancer Institute, Program Leaders Committee
2014-present	Co-Director, Bass Center Tissue Bank
2013-2022	Member, Child Health Research Institute Executive Committee
2014-8/20	Member, Stanford School of Medicine Academic Promotions Committee
2019-8/20	Chair, Stanford School of Medicine Academic Promotions Committee
2020-present	Stanford School of Medicine Physician Scientist Training Program
2020-present	Stanford Science Fellow's Program, Subcommittee for Biosciences
2021-present	Member, Pediatric Hematology/Oncology CME Advisory Board, Stanford University School of Medicine

Honors and Awards

1998	Victor E. Stork Award, Children's Hospital of Los Angeles
1990-1993	Leukemia Society of America Fellowship Award
1991	Leukemia Society of America award as First Designated Researcher supported by the Leukemia Society staff
1992-1995	Jonsson Comprehensive Cancer Center/STOP CANCER Career Development Award
1996-1999	Leukemia Society of America Special Fellow Award
1994	Young Investigator Award in Oncology, American Society for Pediatric Hematology-Oncology
1995	UCLA Frontiers of Science Award
1996	Ross Award in Research By Young Investigators (Western Society for Pediatric Research)
1998-2003	Leukemia Society of America Scholar Award
1998	Participant, AAMC Workshop for Senior Women in Academic Medicine
1999	Invited Participant, American Cancer Society Professors Meeting, October, New York
1996	"Meet-the-Expert", Signal Transduction and Cell Cycle Control in Myeloid Cells, American Society of Hematology, New Orleans, LA
1997	Katherine E. Rogers Scholar for Excellence in Cancer Research, Jonsson Comprehensive Cancer Center, UCLA
1998	AACR-Novartis Scholar in Training Award, Oncogenomics meeting, Tucson, AZ
2001	Keystone Symposium on "Cell Cycle" - Travel Award, Keystone, CO.
2002	AACR-AFLAC Scholar-in-Training Award, meeting on Ubiquitination and Cancer meeting, Vancouver, Canada.
2002	Full member, Molecular Biology Institute, UCLA
2004	Moderator, Leukemia Session at American Society for Pediatric Hematology-Oncology Annual Meeting
2004	Abstract Reviewer and Moderator for "Hematopoiesis: Regulation of Gene Transcription," ASH Meeting
2005-2009	Member, NIH Hematopoiesis Study Section
2005	"Ask the Experts" in Pediatric Cancer, AACR Public Forum, Anaheim, CA.
2005	Chair of Minisymposium, Modulation of Protein Stability. AACR, Anaheim, CA.
2005	Moderator, Pediatric Hematology-Oncology session, PAS/ASPHO meeting, Washington DC, May 2005
2005-2009	Member, ASH Scientific Committee on Myeloid Biology
2006-2010	CDMRP (DOD) CML Grant Review Committee
2006	ASH abstract reviewer on "Hematopoiesis: Regulation of Gene Transcription" for annual meeting
2006	Benjamin Franklin High School Wall of Fame Award
2007	Abstract Coordinating Reviewer, ASH meeting 2007
2007	Stem Cells journal Lead Reviewer Award
2007	Nominated for Who's Who in America
2007	Best Doctors in America
2008	"Meet the Expert" Transcription Factors in Myelopoiesis, ASH meeting
2008	Chair of Cancer Committee, America's Best Children's Hospital, U.S. News & World Report
2008	Pediatric Cancer Research Foundation "Gift of Hope" Award
2008	Who's Who and Super Doctors of Southern California

2009	Fernbach Distinguished Visiting Professor Lectureship, Texas Children's Hospital, Baylor College of Medicine
2010	Outstanding Advance in Cancer Research, Mendiburu Magic Foundation Award
2011	Brent Ely Visiting Professor, Denver Children's Hospital, Colorado
2011	Member, Shwachman Diamond Syndrome Registry Scientific Committee
2012	Shelagh Galligan Endowed Chair
2013	Invited speaker, Swerling Symposium "Seminars in Oncology," Dana Farber Cancer Institute
2013	Jason Bennette Memorial Lectureship, Cohen Children's Hospital, Long Island, NY.
2014	ASH abstract reviewer and moderator for Hematopoiesis: Cytokines, Signal Transduction, Apoptosis, and Cell Cycle Regulation
2014	Donald J. Fernbach Lectureship Series, Baylor College of Medicine
2014	ASH abstract reviewer and session moderator for Hematopoiesis: Cytokines, Signal Transduction, Apoptosis, and Cell Cycle Regulation
2015	Steven Rosen Endowed Lectureship, Northwestern University School of Medicine
2015	Steven Rosen Lectureship, Lurie Cancer Center, Northwestern University
2016	St. Baldrick's Foundation, Scientific Advisory Committee
2016	Pediatric Cancer Research Foundation Memorial Lecture Honoree
2016	Chair, Bear Necessities Scientific Advisory Committee
2017	ASH abstract reviewer and moderator, Committee for Red Cells and Erythropoiesis, Structure and Function, Metabolism, and Survival.
2018	ASH abstract reviewer for Chemical Biology, ASH meeting 2018.
2017-2019	Chair, Physician Scientist Special Interest Group, American Society of Pediatric Hematology/Oncology
2019	UCLA STAR alumni achievement award
2020-2023	NIDDK Council and NIDDK Strategic Plan Working Group of Council
2020	Stanford ChEM-H Innovative Medicines Accelerator Program
2022	Pediatric Residency Program's Honor Role for Teaching, Lucile Packard Children's Hospital Stanford

Scholarly Publications (154 total)

Peer reviewed

1. Nagahashi, G and Hiraike (**Sakamoto**) KM. Effect of centrifugation time on sedimentation of plant organelles. Plant Physiol 69:546-548, 1982.

2. Yamamoto J, Yap J, Hatakeyama J, Hatanaka H, Hiraike (**Sakamoto**) **K**, Wong L: Treating Asian Americans in Los Angeles. Psychiatry 8:411-416, 1985.

3. **Sakamoto KM**, Bardeleben C, Yates KE, Raines MA, Golde DW, Gasson JC: 5' upstream sequence and genomic structure of the human primary response gene, EGR-1/TIS8. Oncogene 6:867-871, 1991.

4. **Sakamoto KM**, Nimer SD, Rosenblatt JD, Gasson JC: HTLV-I and HTLV-II tax *trans*-activate the human EGR-1 promoter through different *cis*-acting sequences. Oncogene 7:2125-2130, 1992.

5. **Sakamoto-K**, Erdreich Epstein A, deClerck Y, Coates T: Prolonged clinical response to vincristine treatment in two patients with idiopathic hypereosinophilic syndrome. Am J Ped Hemat Oncol 14:348-351, 1992.

6. **Sakamoto KM**, Fraser JK, Lee H-J J, Lehman E, Gasson JC. GM-CSF and IL-3 signaling pathways converge on the CREB-binding site in the human EGR-1 promoter. Mol Cell Biol, 14: 5920-5928, 1994.

7. Lee H-J J, Mignacca RM, and **KM Sakamoto**. Transcriptional activation of egr-1 by Granulocyte-Macrophage Colony-Stimulating Factor but not Interleukin-3 requires phosphorylation of CREB on Serine 133. J. Biol. Chem., 270: 15979-15983, 1995.

8. Wong A and **KM Sakamoto**. GM-CSF-Induces the Transcriptional Activation of Egr-1 Through a Protein Kinase A-Independent Signaling Pathway. J Biol Chem 270: 30271-30273, 1995.

9. Horie M, **Sakamoto KM,** Broxmeyer HC. Regulation of egr-1 gene expression by retinoic acid in a human growth factor-dependent cell line. Int J Hematology, 63: 303-309, 1996.

10. Mignacca RC, Lee H-J J, and **KM Sakamoto.** Mechanism of Transcriptional Activation of the Immediate Early Gene Egr-1 in response to PIXY321. Blood, 88: 848-854, 1996.

11. Kao CT, Lin M, O'Shea-Greenfield A, Weinstein J, and **KM Sakamoto.** p55Cdc Overexpression Inhibits Granulocyte Differentiation Through an Apoptotic Pathway. Oncogene, 13:1221-1229, 1996.

12. Kwon EM and **KM Sakamoto**. Molecular Biology of Myeloid Growth Factors. J Inv Med, 44: (8) 442-445 October, 1996.

13. Watanabe S, Kubota H, **Sakamoto KM**, and K Arai. Characterization of cis-acting sequences and trans-acting signals regulating early growth response gene 1 (egr-1) promoter through granulocyte-macrophage colony-stimulating factor receptor in BA/F3 cells. Blood, 89:1197-1206, 1997.

14. Lin M, Mendoza M, Kane L, Weinstein J, and **KM Sakamoto**. Analysis of Cell Death in Myeloid Cells Inducibly Expressing the Cell Cycle Protein p55Cdc. Experimental Hematology 26, 1000-1007, 1998.

15. Weinstein J, Krumm J, Karim, J, Geschwind D, and Nelson SF and **KM Sakamoto**. Genomic Structure, 5'Flanking Enhancer sequence, and chromosomal assignment of cell cycle gene, p55Cdc. Molecular Genetics and Metabolism, 64: 52-57, 1998.

16. Rolli M, Kotlyarov A, **Sakamoto KM**, Gaestel M, and Neininger A. Stress-induced Stimulation of Early Growth Response Gene-1 by p38/Stress-activated Protein Kinase 2 is Mediated by a cAMP-responsive Promoter Element in a MAPKAP Kinase 2-independent Manner. J Biol Chem, 274: 19559-19564, 1999.

17. Chu Y-W, Wang R, Schmid I and **Sakamoto KM**. Analysis of Green Fluorescent Protein with Flow Cytometry in Leukemic Cells. Cytometry, 333-339, 1999.

18. Aicher WK, **Sakamoto KM**, Hack A, and Eibel H. Analysis of functional elements in the human Egr-1 gene promoter. Rheumatology International, 18: 207-214, 1999.

19.Kwon EM, Raines MA and **KM Sakamoto**. GM-CSF Induces CREB Phosphorylation Through Activation of pp90Rsk. Blood, 95: 2552-2558, 2000.

20.Mora-Garcia PM and **KM Sakamoto**. Potential Role of SRF and Fli-1 in G-CSF-induced Egr-1 Gene Expression. J Biol Chem, 275: 22418-22426, 2000.

21. Wu H, Lan Z, Li W, Wu S, Weinstein J, **Sakamoto KM**, Dai W. BUBR1 Interacts with and phosphorylates p55Cdc/hCdc20 in a Spindle Checkpoint-dependent manner. Oncogene, 19:4557-4562, 2000.

22. Wong A, **KM Sakamoto**, and EE Johnson. Differentiating Osteomyelitis and Bone infarctions in sickle cell patients. Ped Em Care, 17:60-66, 2001.

23. Lin M and **KM Sakamoto.** p55Cdc/Cdc20 Overexpression Promotes Early G1/S Transition in Myeloid Cells. Stem Cells19: 205-211, 2001.

24. Shou W, **Sakamoto KM**, Keener J, Morimoto KW, Hoppe GJ, Azzam R, Traverso EE, Feldman RFR, DeModena J, Charbonneau H, Moazed D, Nomura M and RJ Deshaies. RENT complex stimulates RNA Pol I transcription and regulates nucleolar structure independently of controlling mitotic exit. Mol Cell, 8: 45-55, 2001.

25. **Sakamoto KM**, Crews CC, Kim KB, Kumagai A, Mercurio F, and RJ Deshaies. Protac: A Chimeric Molecule that targets Proteins to the SCF for Ubiquitination and Degradation. Proc Natl Acad Sci USA, 98: 8554-8559, 2001.

26. Gubina E, Luo X, Kwon EM, **Sakamoto KM**, Shi YF and RA Mufson. bc Receptor Cytokine Stimulation of CREB Transcription Factor Phosphorylation by Protein Kinase C: A Novel Cytokine Signal Transduction Cascade. J Immunol 167: 4303-4310, 2000.

27. Xu Z, Cziarski R, Wang Q, Swartz K, **KM Sakamoto**, and D Gupta. Bacterial peptidoglycan-induced TNF-a transcription is mediated through the transcription factors Egr-1, Elk-1, and NF-kB. J Immunol, 167: 6972-6985, 2001.

28. Crans H, Landaw E, Bhatia S, Sandusky G, and **KM Sakamoto**. CREB Overexpression in Acute Leukemia. Blood, 99: 2617-2619, 2002.

30. Mendoza MJ, Wang CX, Lin M, Braun J, and **KM Sakamoto**. Fizzy-related RNA expression patterns in mammalian development and cell lines. Mol Genet Metab, 76:3663-366, 2002.

29. Mora-Garcia P, Pan R, and **KM Sakamoto**. G-CSF Regulation of SRE-binding proteins in myeloid leukemia cells. Leukemia, 16: 2332-2333, 2002

31. Lin M, Chang JK, and **KM Sakamoto**. Regulation of the Cell cycle by p55CDC in myeloid cells. Exp Mol Path, 74: 123-8, 2003.

32. Mora-Garcia P, Cheng J, Crans-Vargas H, and **KM Sakamoto**. The role of SRE-binding proteins and CREB in Myelopoiesis, Stem Cells, 21: 123-130, 2003.

33. Hsu H, Rainov NG, Quinones A, Eling DJ, **Sakamoto KM**, and MA Spears. Combined radiation and cytochrome CYP4B1/4-ipomeanol gene therapy using the EGR1 promoter. Anticancer Res 23: 2723-2728, 2003.

34. Countouriotis A, Landaw EM, Naiem F, Moore TB, and **KM Sakamoto**. Comparison of Bone Marrow Aspirates and Biopsies in Pediatric Patients with Acute Lymphoblastic Leukemia at days 7 and 14 of Induction Therapy. Leuk Lymphoma, 45:745-747, 2004.

35. **Sakamoto KM**, Kim KB, Verma R, Ransick A, Stein B, and RJ Deshaies. Development of Protacs to Target Cancer-Promoting Proteins for Ubiquitination and Degradation. Mol Cell Proteomics, 12:1350-1358, 2003.

36. Wang Q, Liu T, Fang Y, Xie S, Huang X, Mahmood R, Ramasywamy G, **Sakamoto KM**, Darynkiewicz Z, Xu M, and W Dai. BUBR1-deficiency results in Abnormal Megakaryopoiesis. Blood, 103: 1278-1285, 2004.

37. Schneekloth JS, Fonseco F, Koldobskiy M, Mandal A, Deshaies RJ, **Sakamoto KM**, CM Crews. Chemical Genetic Control of Protein Levels: Selective *in vivo* Targeted Degradation. J Amer Chem Soc, 126(12); 3748-3754, 2004.

38. Verma R, Peters NR, Tochtrop G, **Sakamoto KM**, D'Onofrio, Varada R, Fushman D, Deshaies RJ, and RW King. Ubistatins, a Novel Class of Small Molecules that inhibit Ubiquitin-Dependent Proteolysis by Binding to the Ubiquitin Chain. Science, 306:117-120, 2004.

39. Cheng JC, Esparza SD, Knez VM, **Sakamoto KM**, and TBMoore. Severe Lactic Acidosis in a 14-year old female with Metastatic Undifferentiated Carcinoma of Unknown Primary. Am J Ped Hem Onc, 26:780-782, 2004.

40. Mora-Garcia P, Wei J, and **KM Sakamoto**. G-CSF Induces Stabilization of Ets Protein Fli-1 During Myeloid Cell Development. Pediatr Res, 1:63-66, 2005.

41. Shankar D, Cheng J, Kinjo K, Wang J, Federman N, Gill A, Rao N, Moore TB, Landaw EM and **KM Sakamoto**. The role of CREB as a proto-oncogene in Hematopoiesis and in Acute Myeloid Leukemia. Cancer Cell, 7:351-362, 2005.

42. Shankar D, Cheng JC, and **KM Sakamoto**. The Role of Cyclic AMP Response Element Binding Protein in Human Leukemias. Cancer, 104:1819-1824, 2005.

43. Kinjo K, Sandoval S, **KM Sakamoto** and DB Shankar. CREB as a Proto-oncogene in Hematopoiesis. Cell Cycle, 4: 1134-1135, 2005.

44. **Sakamoto KM.** Chimeric Molecules to Target Proteins for Ubiquitination and Degradation. Methods in Enzymology (Ubiquitin and Proteasome System), 299C: 833-837, 2005.

45. **Sakamoto KM**. Academic Training Pathways in Pediatric Hematology-Oncology. Pediatric Blood and Cancer, Nov 7, 2005.

46. Priceman SJ, Kirzner JD, Nary LJ, Morris D, Shankar DB, **Sakamoto KM**, and RD Medh. Calcium-Dependent Up Regulation of E4BP4 Expression Correlates With Glucocorticoid-Evoked Apoptosis of Human Leukemic CEM Cells. BBRC, 344(2):491-9. Epub 2006 Apr 5.

47. Shankar DB, Li J, Tapang P, McCall JO, Pease LJ, Dai Y, Wei RQ, Albert DH, Hartandi K, Michaelides M, Davidsen SK, Priceman S, Chang J, Shah N, Moore TB, **Sakamoto KM***, and KB Glaser. ABT-869 a Multi-Targeted Receptor Tyrosine Kinase Inhibitor: Inhibition of FLT3 Phosphorylation and Signaling in AML, Blood, 109: 3400-3408, 2007 (*co-senior author).

48 Cheng JC, Horwitz EM,…. Kornblum H, Malik P, **KM Sakamoto**. New Technologies in Stem Cell Research. Meeting report from Society for Pediatric Research meeting (April 2006), Stem Cells.

49. Cheng JC, Esparza SD, Sandoval S, Shankar DB, and **KM Sakamoto**. The potential role of CREB as a prognostic marker in leukemia. Future Oncology, 3:475-80, 2007.

50. Yang Z, Jiang H, Zhao F, Shankar DB, **Sakamoto KM**, Zhang MQ, and S Lin. A highly conserved distal regulatory element controls hematopoietic expression of *GATA-2*. BMC Developmental Biology, 7:97, 2007.

51. Lin TL, Fu C, and **KM Sakamoto**. Cancer Stem Cells: the root of the problem. Peds Res, 62:239, 2007

52. Esparza S, Chang J, Shankar D, Zhang B, Nelson S, and **KM Sakamoto**. CREB regulates Meis1 Expression in Normal and Malignant Hematopoietic Cells, Leukemia, Sept 6; Epub, 2007.

53. Cheng JC, Kinjo K, Wu WS, Schmid I, Shankar DB, Stripecke R, Kasahara N, Bhatia R, Landaw EM, Nelson S, Pelligrini M, and **KM Sakamoto**. CREB is a critical regulator of normal hematopoiesis and leukemogenesis, Blood, 111:1182-1192, 2008.

54. Rodriguez-Gonzalez A, Lin T, Ikeda AK, Simms-Waldrip T, Fu C, and **KM Sakamoto**. Role of the Aggresome Pathway in Cancer: Targeting HDAC6 for therapy. Cancer Research, 15: 2557-2560, 2008.

55. Simms-Waldrip T, Rodriguez-Gonzalez A, Lin T, Ikeda AK, Fu C, and **KM Sakamoto**. Targeting the Aggresome Pathway in Hematologic Malignancies. Mol Gen Metab, 94:283-286, 2008**.**

56. Rajasekaran SA, Christiansen JJ, Schmid I, Oshima E, **Sakamoto KM**, Weinstein J, Rao NP, Rajasekaran AK. Prostate specific membrane antigen associates with anaphase-promoting complex and induces chromosomal instability. Mol Cancer Ther, 7:2142-51, 2008.

57. Danilova N, **Sakamoto KM**, and S Lin. Ribosomal protein S19 deficiency in zebrafish leads to developmental abnormalities and defective erythropoiesis through activation of p53 protein family. Blood, Epub May 30, 112(13):5228-37, 2008.

58. Pellegrini M, Cheng JC, Voutila J, Judelson D, Taylor JA, Nelson SF, and **KM Sakamoto**. Expression Profile of CREB knockdown in Myeloid Leukemia Cells. BMC Cancer, 18;8:264, 2008 [Epub].

59. Rodriguez-Gonzalez A, Cyrus K, Salcius M, Kim KB, Crews CM, Deshaies RJ, and **KM Sakamoto**. Targeting Steroid Hormone Receptors for Ubiquitination and Degradation in Breast and Prostate Cancer, Oncogene, 27:7201-11, 2008.

60. Danilova N, **Sakamoto KM**, and S Lin. Role of p53 Family in Birth Defects: Lessons from Zebrafish. Birth Defects Research (Part C), 84:215-27, 2008.

61. Danilova, N., **KM Sakamoto**, and S. Lin, p53 family in development, Mech Development, 125:919-31, 2008.

62. Sandoval S, Pigazzi M, and **KM Sakamoto**. CREB: A Key Regulator of Normal and Neoplastic Hematopoiesis. Adv Hematol, 2009:634292, 2009.

63. Ikeda AI, Judelson D, Federman N, Glaser K, Landaw EM, Denny CT, and **KM Sakamoto**. ABT-869 Suppresses Proliferation of Ewing Sarcoma cells by Inhibiting PDGFRb and c-KIT-dependent Pathways. Mol Cancer Ther, 9:653-660, 2010.

66. Xiao X, Li BX, Mitton B, Ikeda A, and **KM Sakamoto**. Targeting CREB for Cancer Therapy: Friend or Foe. Curr Cancer Drug Targets, 10: 384-391, 2010.

67. Wu WKK, **Sakamoto KM**, Milani M, Aldana-Masangkay G, Fan D, Wu K, Le CW, Cho CH, Yu J, Sung JJY. Macroautophagy modulates cellular response to proteasome inhibitors in cancer therapy. Drug Resistance Updates (Impact factor 9.4), May 10, 2010 [Epub ahead of print].

68. Niemeyer CM, Kan MW, Shin DH, Furlan I, Erlacher M, Bunin NJ, Bunda S, Finklestein JZ, **Sakamoto KM**, Gorr TA, Mehta P, Schmid I, Kropshofer G, Corbacioglu S, Lang PJ, Klein C, Schlege PG, Heinzmann A, Schneider M, Stary J, van den Heuvel-Eibring MM, Hasle H, Locatelli F, Sakai D, Archambeault S, Chen L, Russell RC, Sybingco SS, Ohh M, Braun BS, Flotho C, and ML Loh. Germline CBL mutations cause developmental abnormalities and predicspose to Juvenile myelomonocytic leukemia. Nat Genet, 42:794-800, 2010.

69. Wen AY, **Sakamoto KM**, and LS Miller. The Role of the Transcription Factor CREB in Immune Function. J Immunol, 185(11): 6413-9, 2010.

70. Lin TL, Wang Q, Brown P, Peacock C, Merchant AA, Brennan S, Jones E, McGovern K, Watkins DN, **Sakamoto KM**, and W Matsui. Self-renewal of acute lymphocytic leukemia cells is limited by the Hedgehog pathway inhibitors cyclopamine and IPI-926. PLoS One, 5(12):e15262, 2011.

71. Aldana-Masangay GI and **KM Sakamoto**. The Role of HDAC6 in Cancer, J Biomed Biotechnol, 2011:875824, 2010.

72. Frugé, E., Lakoski, J.M., Luban, N., Lipton, J.M., Poplack, D., Hagey, A. , Felgenhauer, J., Hilden, J., Margolin, J., Vaiselbuh, S. R., and **Sakamoto, KM**. Increasing Diversity in Pediatric Hematology/Oncology. Ped Blood Cancer, 57:147-152, 2011.

73. Morimoto K, TB Moore, Schiller G, and **KM Sakamoto.** Transplantation Outcomes in Congenital Bone Marrow Failure syndromes. Bone Marrow Res, 2011:849387, 2011.

74. Danilova N, **Sakamoto KM**, S Lin. Ribosomal protein L11 mutation in zebrafish leads to haematopoietic and metabolic defects. Br J Haematol 152:217-228, 2011.

75. Aldana-Masangkay G, Rodriguez-Gonzalez A, Lin T, Ikeda AK, Hsieh YT, Kim YM, Lomenick B, Okemoto K, Muschen M, Landaw E, Wang D, Mazitschek R, Bradner JE, and **KM Sakamoto**. Tubacin Suppresses Proliferation and Induces Apoptosis of Acute Lymphoblastic Leukemia Cells. Leuk Lymphoma, 52:1544-1555, 2011.

76. Hernandez JE, Zape JP, Landaw EM, Tan A, Presnell A, Griffith D, Heinrich MC, Glaser KB, and **KM Sakamoto**. The multi-targeted receptor tyrosine kinase inhibitor, Linifanib (ABT-869), induces apoptosis through an AKT and Glycogen Synthase Kinase 3β-dependent pathway. Mol Cancer Ther, 10:949-959, 2011.

77. Mitton B, Cho ED, Aldana-Masangkay GI, and **KM Sakamoto**. The function of cyclic adenosine monophosphate responsive element binding protein in hematologic malignancies. Leuk Lymphoma 52:2057-63, 2011.

78. Sandoval S, Kraus C, Cho EC, Cho M, Bies Juraj, Landaw EM, Wolff L, and **KM Sakamoto**. Sox4 cooperates with CREB in Myeloid Transformation, Blood, 120: 155-165, 2012.

79. Pigazzi M, Manara E, Bresolin S, Trgnago C, Behin A, Baron E, Giarin E, Cho EC, Masetti R, Rao DS, **KM Sakamoto** * and G Basso* (*co-senior authors). MiR34b hypermethylation induces CREB overexpression and contributes to myeloid transformation. Haematologica, 98:602-610, 2013.

80. Chang VY, Basso G, **Sakamoto KM***, and SF Nelson*(*co-senior authors) Identification of Somatic and Germline Mutations using Whole Exome Sequencing of Congenital Acute Lymphoblastic Leukemia. BMC Cancer, Feb 4, 13:55, 2013.

81. Wen AY, Landaw EM, Ochoa R, Cho M, Chao A, Lawson, and **KM Sakamoto**. Increased Ascess Formation and Defective Chemokine Regulation in CREB Transgenic Mice. PLoS One, 8:e55866, 2013.

82. Martinez-Flores F, Barrera-Lopez A, Sandoval-Zamora H, Garcoa-Cavazos R, Franco-Bourland R, Madenaveitia J, Zentella-Dehesa A, Curiel DT, and **K. Sakamoto**. Activity of Egr-1 promoter induced by UV light in human primary dermal fibroblasts transduced with ad-Egr-1/Luc is repressed by betamethasone. Gene Therapy Mol Biology, 14:92-106, 2013.

83. Reiss UM, Schwartz J, **Sakamoto KM**, Puthenveetil G, Ogawa M, Bedrosian CL, and RE Ware. Efficacy and safety of eculizumab in children and adolescents with parosysmal nocturnal hemoglobinuria. Pediatr Blood Cancer, April 29, 2014. [Epub ahead of print]

84. Danilova N, Bibikova E, Covey TM, Nathanson D, Dimitrova E, Lindgren A, Glader B, Radu CG, **Sakamoto KM**, and S Lin. The Role of DNA damage response in zebrafish and cellular models of Diamond Blackfan Anemia. Disease Models and Mechanisms, 7:895-905, 2014.

85. Bibikova E, Youn MY, Danilova N, Konto-Ghiorghi Y, Ono-Uruga Y, Ochoa R, Narla A, Glader B, Lin S*, and **KM Sakamoto*** (*co-senior authors). TNF-α mediated inflammation in RPS19 deficient hematopoietic progenitors represses GATA1 through a p53-dependent mechanism. Blood, 124:3791-3798, 2014.

86. Chae HD, Mitton BA, and **KM Sakamoto**. Replication factor C3 is a CREB Target Gene that Enhances G1/S Transition of AML cells and Self-renewal of Hematopoietic Stem and Progenitor Cells. Leukemia, 29:1379-1389, 2015.

87. Kim PG, Rowe RG, Nakano H, Chou SC, Ross SJ, Chen MJ, **Sakamoto KM**, Zon LI, Nakano A, and GQ Daley. Flow-induced Protein Kinase A/CREB pathway acts via BMP signaling to promote AGM hematopoiesis. J Exp Med, 212:633-648, 2015.

88. **Sakamoto KM**, Grant S, Saleiro D, Crispino JD, Hijiya N, Giles F, Platanias L, Eklund EA. Targeting novel signaling pathways for resistant acute myeloid leukemia. Mol Genet Metab, 114:397-402, 2015.

89. Rankin EB, Narla A, Park JK, Lin S and **KM Sakamoto**. Biology of the Bone Marrow Microenvironment and Myelodysplastic Syndromes. Mol Gen Metab, 115:24-28, 2015.

90. Klenk C, Gawande R, Tran VT, Trinh J, Chi K, Owen D, Luna-Fineman S, **Sakamoto KM**, McMillan A, Quon A, and HE Daldrup-Link. ^{18}F-FDG PET/MR for local staging of pediatric malignancies: Which imaging components are complementary or equivalent? J Nuc Med, 57:70-77, 2016.

91. Mitton BM, Hsu K, Dutta R, Tiu BC, Cox N, Mclure KG, Chae HD, Smith M, Eklund EA, Solow-Cordero DE, and **KM Sakamoto**. Small Molecule Screen for Inhibitors of the Transcription Factor, CREB. Oncotarget, 7:8653-8662, 2016.

92. Huang W, Luan CH, Elizabeth Hjort E, Ling Bei L, Rama Mishra R, **Sakamoto KM**, Leonidas Platanias, and Elizabeth Eklund. The role of Fas-associated phosphatase 1 in leukemia stem cell-persistence during tyrosine kinase inhibitor-treatment of chronic myeloid leukemia, Leukemia, Mar 17 2016.

93. Zweidler-McKay PA, Hogan MS, Jubran R, Black V, Casillas J, Harper J, Malempati S, Margolin J, Felgenhauer J, **Sakamoto KM**, Franklin J, Shah M, Seibel N, Buchanan G, Vaiselbuh SR, Hastings C, Hliden J, and LC Stork. Navigating your career path in pediatric hematology/oncology: On and off the beaten track. Pediatr Blood Cancer 63:1723-1730, 2016.

94. Mitton B, Chae HD, Hsu K, Dutta R, Aldana-Masangkay G, Ferrari R, Davis K, Breese M, Lacayo N, Dahl G, Xie F, Li B, Landaw E, Nolan G, Pellegrini M, Xiao X, and **KM Sakamoto**. Disruption of CREB-CBP Interaction by a Novel Small Molecule Induces Cell Cycle Arrest and Apoptosis of Acute Myeloid Leukemia Cells. Leukemia, Jun 10 2016.

95. Ear J, Hseuh J, Nguyen M, Zhang Q, Sung V, Chopra R, **Sakamoto KM**, and **S Lin**. A Zebrafish Model of 5q- Using CRISPR/Cas9 Targeting RPS14 reveals a p53-independent and p53-dependent mechanism of Erythroid Failure. J Genet Genomics, 43:307-318, 2016.

96. Francois S, Sen N, Mitton B, Xiao X, **Sakamoto KM**, and A Arvin. Varicella-Zoster Virus Activates CREB and Inhibition of the pCREB-p300/CBP- Interaction Inhibits Viral Replication in vitro and Skin Pathogenesis in vivo. J Virology, 90:8686-8697, 2016.

97. Dutta R, Tiu B and **Sakamoto KM**. CBP/p300 acetyltransferase activity in hematologic malignancies. Mol Genet Metab Jun 30 2016.

98. Youn M, Wang N, LaVasseur C, Bibikova E, Kam S, Glader B, **Sakamoto KM***, and A Narla*. Loss of FOXM1 promotes erythropoiesis through increased proliferation of erythroid progenitors. Haematologica, 2017 Feb 2. pii: haematol.2016.156257. doi: 10.3324/haematol.2016.156257. *co-senior authors.

99. Wilkes MC, Repellin CE and **Sakamoto KM**. Beyond mRNA: The role of non-coding RNAs in normal and aberrant hematopoiesis. Mol Genet Metab. S1096-7192, 2017.

100. Chae HD, Cox N, Dahl GV, Lacayo NJ, Davis KL, Capoliccio S, Smith M, and **KM Sakamoto**. Niclosamide Suppresses Acute Myeloid Leukemia Cell Proliferation Through Inhibition of CREB-Dependent Signaling Pathways. Oncotarget, 9:4301-4317, 2017 (published as a Priority Paper).

101. Danilova N, Wilkes M, Bibikova E, Youn MY, **Sakamoto KM***, and Lin S*. Innate Immune System Activation in Zebrafish and Cellular Models of Diamond Blackfan Anemia. Sci Rep, 8(1):5165, 2018. *co-senior authors.

102. Duque-Alfonso J, Lin CH, Han K, Morgens DW, Jeng EE, Weng Z, Jeong J, Wong SHK, Zhu L, Wei MC, Chae HD, Schrappe M, Cario G, Duyster J, Xiao X, **Sakamoto KM**, Bassic ML and ML Cleary. CBP modulates dasatinib sensitivity in pre-BCR+ acute lymphoblastic leukemia. Cancer Res, 78:6497-6508, 2018.

103. Chae HD, Cox N, Capolicchio S, Lee JW, Horikoshi N, Kam S, Ng A, Edwards J, Butler TL, Chan J, Lee Y, Potter G, Capece M, Liu C, Wakatsuki S, Smith M and **KM Sakamoto**. Salicylamide as a potential treatment for acute myeloid leukemia through inhibition of the CREB pathway. Bioorg Med Chem Letters, 29:2307-2315, 2019.

104. Youn MY, Huang H, Chen C, Kam S, Wilkes MC, Chae HD, Sridhar KJ, Greenberg PL, Glader B, Narla A, Lin S* and **KM Sakamoto***. MMP9 Inhibition increases erythropoiesis in RPS14-deficient del(5q) MDS models through suppression of TGF-beta pathways. Blood Advances, 3:2751-2763, 2019.

105. Huang M, Zeki J, Sumarsono N, Coles GL, Taylor JS, Danzer E, Bruzoni M, Hazard FK, Lacayo NJ, **Sakamoto KM**, Dunn JCY, Spunt SL and B Chiu. Epigenetic Targeting of Tert-Associated Gene Expression Signatures in Human Neuroblastoma with Tert Overexpression. Canc Res, Jan 3, 2020.

106. Wojcicki AV, Kadapakkam M, Frymoyer A, Lacayo N, Chae HD and **KM Sakamoto**. Repurposing drugs for Acute Myeloid Leukemia: A Worthy Cause or a Futile Pursuit? Cancers (Basel), 12:441, 2020.

107. Wojcicki AV, Kasowski MM, **Sakamoto KM** and N Lacayo. Metabolomics in acute myeloid leukemia. Mol Genet Metab, May 18:1096-7192, 2020.

108. Chae HD, Dutta R, Tiu B, Hoff F, Accordi B, Serafin V, Youn MY, Huang M, Sumarsono N, Davis KL, Lacayo NJ, Pigazzi M, Horton TM, Kornblau SM and **KM Sakamoto**. RSK Inhibitor BI-D1870 Inhibits Acute Myeloid Leukemia Cell Proliferation by Targeting Mitotic Exit. Oncotarget, 11:2387-2403, 2020.

109. Wilkes MC, Siva K, Chen J, Varetti G, Dever DP, Nishimura T, Chae H, Youn MY, Narla A, Glader B, Nakauchi H, Porteus MH, Repellin CE, Gazda TH, Lin S, Serrano M, Flygare J and **KM Sakamoto**. Diamond Blackfan Anemia is Mediated by Hyperactive Nemo-Like Kinase. Nat Commun, 11:3344, Jul 3, 2020.

110. Wilkes MC, Siva K, Varetti G, Mercado J, Wentworth EP, Perez C, Saxena M, Km S, Kapur S, Chen J, Narla A, Glader B, Lin S, Serrano M, Flygare J and **KM Sakamoto**. Metformin-induced Suppression of NLK improves Erythropoiesis in Diamond Blackfan Anemia through Induction of miR26a, Exp Hematol, Sep 12, 2020.

111. Ding YY, Ramakrishna S, Long AH, Phillips CA, Montiel-Esparza R, Diorio CJ, Bailey LC, Maude SL, Aplenc R, Bara V, Reilly AF, Rheingold SR, Lacayo NJ, **Sakamoto KM**, Hunger SP. *co-senior authors Pediatric Blood Cancer, 67:e28427, 2020.

112. Dualt C, Kumar A, Khani A, Lee SJ, Yang L, Huang M, Manning B, Hurtz C, Ghoda L, McDonald T, Lacayo NJ, **Sakamoto KM**, Carroll M, Marcucci G, Yu J, Caligiuri MA, Maecker

HT, S Swaminathan. Activated Natural Killer Cells with Impaired Cytolytic Potential Predict Poor Clinical Prognosis in High-risk B- and T-cell Acute Lymphoblastic Leukemia. Blood, Jun 2, 2021.

113. Smith SM, Sabnis HS, Lewis RW, Effinger KE, Bergsagel J, Patterson B, Mertens A, **Sakamoto KM**, Schapira L, and SM Castellano. Patterns of Surveillance for late effects of BCR-ABL tyrosine kinase inhibitors in pediatric Philadelphia chromosome positive leukemias. BMC Cancer, 21:474, 2021.

114. Youn MY, Gomes JO, Mark K and **KM Sakamoto**. RSK Isoforms in Acute Myeloid Leukemia, Biomedicines, 9:726, 2021.

115. Wilkes MC, Jung K, Lee BE, Saxena M, Sathianathen R, Varetti G, Mercado J, Perez C, Flygare J, Serrano M, Narla A, Glader B, **Sakamoto KM**. The Active Component of Ginseng, Ginsenoside Rb improves erythropoiesis in models of Diamond Blackfan Anemia by targeting Nemo-like Kinase. J Biol Chem, 297: 100988, 2021.

116. Wilkes MC, Shibuya A, **Sakamoto KM**. Signaling Pathways that Regulate Normal and Aberrant Red Blood Cell Development. Genes (Basel); 12:1646, 2021.

117. Smith SM, Zhang K, Sundaram V, Roth M, Andolina JR, Schapira L, **Sakamoto KM**, Kolb EA, Hijiya N, Chaudhury S. Physician Risk Perceptions and Surveillance Practices for TKI-Associated Long-Term Effects in Pediatric CML. Pediat Hemat Oncol, 17:1-15, 2021.

118. Shibuya A, Wilkes MC, Narla A*, **Sakamoto KM*.** Targeting Nemo-like Kinase for the Potential Treatment of Diamond Blackfan Anemia. Stem Cell and Therapy, *in press*. *co-senior authors.

119. Zhang K, Horikoshi N, Shanshan L, Powers AS, Pintilie GD, Chae HD, Khan YA, Suomivuori CM, Dror RO, **Sakamoto KM***, Chiu W* and S Wakatsuki*. Achieving near-atomic reosolution Cryo-EM structure of an 11-kDa flexible protein to guide drug discovery, ACS Central Science, 8:214-222, 2022. * Co-Senior Authors.

120. Heitzeneder S, Bosse KR, Zhu Z, Zhelev D, Majzner RG, Radosevich MT, Dhingra S, Sotillo E, Buongervino S, Pascual-Pasto G, Garrigan E, Xu P, Huang J, Salzer B, Delaidelli A, Raman S, Cui H, Martinez B, Bornheimer SJ, Sahaf B, Alag A, Fetahu IS, Hasselblatt M, Parker KR, Anbunathan H, Hwang J, Huang M, **Sakamoto K**, Lacayo NJ, Klysz DD, Theruvath J, Vilches-Moure JG, Satpathy AT, Chang HY, Lehner M, Taschner-Mandl S, Julien JP, Sorensen PH, Dimitrov DS, Maris JM, Mackall CL. GPC2-CAR T cells tuned for low antigen density mediate potent activity against neuroblastoma without toxicity. Cancer Cell. 2022 Jan 10;40(1):53-69.e9. doi: 10.1016/j.ccell.2021.12.005. Epub 2021 Dec 30.

121. Youn MY, Smith SM, Chae HD, Lee AG, Murphy LC, Donato M, Sweet-Cordero A, Abidi Parveen, Bittencourt H, Lacayo N, Dahl G, Aftandilian C, Davis K, Matthews JA, Kornblau SM, Huang M, Sumarsono N, Redell MS, Fu CH, Chen IM, Alonzo T, Eklund EA, Gotlib JR, Khatri P, Hijiya N and **KM Sakamoto**. Comparison of the Transcriptomic Signatures in Pediatric and Adult CML. Cancers (Basel), 13:6263.

122. Ayyadurai S, Deonikar P, Mclure K and **KM Sakamoto**. Molecular Systems Architecture of the Interactome in the Acute Myeloid Leukemia Microenvironment. Cancers (Basel), 14:756, 2022..

123. Lo YC, Jager A, Keyes TJ, Sarno J, Domizi P, Majeti R, **Sakamoto KM**, Lacayo N, Mulligan CG, Sahaf B, ….Bendall SC and KL Davis. Batch Normalization using Generalized Anchors for Integration of Mass Cytometry Data from Public Database. Nature Commun, 13:945, 2022.

124. Wilkes MC, Scanlon V, Shibuya A, Celika AM, Eskin A, Chen Z, Narla A, Glader B, Roncarolo MG, Nelson SF, and **KM Sakamoto**. Downregulation of SATB1 by miRNAs Reduces Megakaryocyte/Erythroid Progenitor Expansion in pre-clinical models of Diamond Blackfan Anemia. Exp Hematol, 111:66-78, 2022.

125. Ford M, Aftandilian C, Mauro M, **Sakamoto KM***, Hijiya N*. Management of Chronic Myeloid Leukemia in Children and Young Adults. Current Hematologic Malignancy Reports (Springer), 17: 121-126. *co-senior authors.

126. Reschke A, Richards RM, Smith SM, Long AH, Marks LJ, Schultz L, Kamens JL, Aftandilian C, Davis KL, Gruber T, **Sakamoto KM**. Development of Clinical Pathways to Improve Multidisciplinary Care of Pediatric Oncology Patients. Frontiers in Oncology, 12: 1033993, 2022.

127. Wilkes MC, Scanlon V, Shibuya A, Celika AM, Eskin A, Chen Z, Narla A, Glader B, Roncarolo MG, Nelson SF, and **KM Sakamoto**. (2022). Downregulation of SATB1 by miRNAs Reduces Megakaryocyte/Erythroid Progenitor Expansion in pre-clinical models of Diamond Blackfan Anemia. Exp Hematol, 111:66-78. PMID 35460833

128. Liu Y Lucy, Shibuya A, Glader B, Wilkes M, Barna M, **Sakamoto KM**. Animal Models of Diamond-Blackfan Anemia: Updates and Challenges. Haematologica, Nov 17, 2022.

129. Tal A, Moerdler S, Fernandez CR, Dome JS, **Sakamoto KM**. Can you hear me now? Cultivating a culture of respect, value, and appreciation with pediatric hematology, oncology, and cellular therapy, Ped Blood Cancer, 70: e30127, 2023.

130. Wilkes MC, Chae HD, Scanlon V, Cepika AM, Wentworth EP, Saxena M, Chen Z, Glader B, Roncarolo MG, Nelson SF, **Sakamoto KM**. SATB1 Regulation of Hematopoiesis in Diamond Blackfan Anemia, Stem Cells, *in press*.

131. Natarajan A, Fremin BJ, Schmidtke DT, Wolfe M, Zlitni S, Graham KE, Brooks EF, Severyn CJ, **Sakamoto KM**, Lacayo NJ, Kuersten S, Koble J, Caves G, Kaplan I, Rezvani AR, Bhatt AS, Boehm A. Tomato brown rugose fruit virus Mo gene is a novel microbial source tracking marker. App Environ Microbiology, *in press*

132. Sinha R, Dvorak M, Niemeyer C, Flotho C, **Sakamoto KM**, Lacayo N, Patil R, Perrimen R, Liu L, Alma-Martina C, Utz PJ, Kuo A, Bertaina A. Epigenetic profiling of *PTPN11* mutant JMML hematopoietic stem and progenitor cells through EpiTOF reveals an aberrant histone landscape as a new putative mechanism of leukemogenesis, *submitted*.

133. Kumar A, Dualt C, Khani AT, Ortiz AS, Lee SJ, Chan, Araburo, McDonald T, Huang M, Lacayo NJ, **Sakamoto KM**, Yu J, Caligiuri MA, Hurtz C, Carroll M, Tasian SK, Ghoda L, Marcucci G, Gu Z, Rosen ST, Armenian S, Izraeli S, Chen CW, Forman SJ, Maecker HT, S Swaminathan. IL-15-producing NK cells counter the intrinsic suppression of type I interferons in B-cell lymphoblastic leukemia. J ImmunoTherapy, *in press.*

Non peer reviewed

1. **Sakamoto KM**, Golde DW, Gasson JC: The biology and clinical applications of granulocyte-macrophage colony-stimulating factor. J Peds 118:S17-S20, 1991.

2. **Sakamoto KM**, Gasson JC: Clinical applications of human granulocyte-macrophage colony-stimulating factor. Int J Cell Cloning 9:531-541, 1991.

3. **Sakamoto KM**, Mignacca RC, Gasson JC: Signal transduction by granulocyte-macrophage colony-stimulating factor and interleukin-3 receptors. Receptors and Channels, 2: 175-181, 1994.

4. Mora-Garcia P and **KM Sakamoto**. Signal Transduction and Human Disease. Molecular Genetics and Metabolism, 66, 143-171, 1999.

5. Chu Y-W, Korb J and **KM Sakamoto**. Immune Thrombocytopenia Purpura. Pediatrics In Review, 21: 95-104, 2000.

6.**Sakamoto, KM**. Genetic and Functional Consequences of Cell Cycle Alteration in Cancer-AACR Special conference. 20-24 October 1999, San Diego, CA, USA. Idrugs 2000 3: 36-40.

7.Vu PK and **KM Sakamoto**. Ubiquitin-Mediated Proteolysis and Human Disease, Mol Gen Metab, 71: 261-266, 2000.

8. Crans H and **KM Sakamoto**. Transcription factors and Translocations in lymphoid and myeloid leukemia. Leukemia, 15: 313-331, 2001.

9. Shankar D and **KM Sakamoto**. Cell cycle control in normal and malignant hematopoiesis. Recent Advances in Blood Research, 1:47-71, 2001.

10. Countouriotis A, Moore TB, and **KM Sakamoto**. Molecular targeting in the treatment of hematologic malignancies. Stem Cells, 20:215-229, 2002.

11. **Sakamoto KM**. Ubiquitin-dependent proteolysis: its role in human diseases and the design of therapeutic strategies. Mol Genet Metab 77:44-56, 2002.

12. **Sakamoto KM**. Targeting Ubiquitinylation for Drug Discovery. Meeting review, Idrugs 5: 779-781, 2002.

13. Cheng J, Moore TB, and **KM Sakamoto**. RNA interference and Human Disease. Mol Genet Metab, 80: 121-128, 2003.

14. Shankar D and **KM Sakamoto**. The Role of Cyclic-AMP Binding Protein (CREB) in leukemia cell proliferation and acute leukemias. Leuk Lymphoma, 45:265-70, 2004

15. **Sakamoto KM**. Knocking Down Human Disease: Potential uses of RNAi in Research and Gene Therapy. Pediatr Res, 55:912-913, 2004.

16. Cheng JC and **KM Sakamoto**. The Emerging Role of RNA Interference in the Design of Novel Therapeutics in Oncology (invited review), Cell Cycle, 3: 1398-1401, 2004.

17. **Sakamoto KM**. A Pediatric Approach to Classification of MDS. Highlights of the American Society of Pediatric Hematology-Oncology 17th Annual Meeting, May 2004. Medscape from WebMD.

18. **Sakamoto KM**. Understanding the Pathophysiology of Marrow Failure in MDS. Highlights of the American Society of Pediatric Hematology-Oncology 17th Annual Meeting, May 2004. Medscape from WebMD.

19. **Sakamoto KM**. Clinical Aspects of Childhood MDS. Highlights of the American Society of Pediatric Hematology-Oncology 17th Annual Meeting, May 2004. Medscape from WebMD.

20. Esparza SD and **KM Sakamoto**. Topics in Pediatric Leukemia-Acute Lymphoblastic Leukemia. MedGenMed Hematology-Oncology, published online on Medscape from WebMD, 2005.

21. Casillas J and **KM Sakamoto**. Topics in Pediatric Leukemia-Acute Lymphoblastic Leukemia and Late Effects in Long-Term Survivors. MedGenMed Hematology-Oncology, published online on Medscape from WebMD, 2005.

22. Lasky J and **KM Sakamoto**. Topics in Pediatric Leukemia-Myelodysplastic and Myeloproliferative Disorders of Childhood. MedGenMed Hematology-Oncology, published online on Medscape from WebMD, 2005.

23. Cheng JC and **KM Sakamoto**. Topics in Pediatric Leukemia-Acute Myeloid Leukemia. MedGenMed Hematology-Oncology, published online on Medscape from WebMD, 2005.

24. Moore TB and **KM Sakamoto**. Topics in Pediatric Leukemia-Hematopoietic Stem Cell Transplantation. MedGenMed Hematology-Oncology, published online on Medscape from WebMD, 2005.

25. Federman N and **KM Sakamoto**. Topics in Pediatric Leukemia-Fanconi's Anemia: New Insights. MedGenMed Hematology-Oncology, published online on Medscape from WebMD, 2005.

26. Federman N and **KM Sakamoto**. The Genetic Basis of Bone Marrow Failure Syndromes in Children, Mol Gen Metab, 76:3663-366, 2005.

27. Parcells B, Ikeda AK, Simms-Waldrip T, Shankar DB, Moore TB, and **KM Sakamoto**. The Role of FLT3 in Normal Hematopoiesis and AML, Stem Cells, 24(5):1174-84, 2006.

28. Ikeda AK, Simms-Waldrip T, Shankar DB, Watanabe M, Tamanoi F, Moore TB, and **KM Sakamoto**. Molecular Targets and the Treatment of Acute Myeloid Leukemia, Mol Gen Metab, 88:216-224, 2006.

29. Morimoto K, Lin S, and **KM Sakamoto**. The Functions of RPS19 and Their Relationship to Diamond-Blackfan Anemia: A Review. Mol Gen Metab, Dec 16, 2006 [epub].

30. Fu C and **KM Sakamoto**. Peg-Asparaginase (Invited Review). Expert Opinion on Pharmacotherapy, 8: 1977-1984, 2007.

31. Gawad C, Fu C, and **KM Sakamoto**. Emerging Immunotherapeutic Strategies to Treat Pediatric AML. Touch Briefings in US Pediatrics Review, 2007.

32. **Sakamoto KM** and D Frank. CREB in the pathophysiology of cancer: implications for targeting transcription factors for cancer therapy. Clin Cancer Res, 2583-2587, 2009.

33. **Sakamoto, K.M**. Protacs for Treatment of Cancer. Annual Review Issue of Pediatric Research on Nanopediatrics, Jan 13, 2010 [Epub].

34. **Sakamoto KM**, Shimamura A, and SM Davies. Congenital Disorders of Ribosome Biogenesis and Bone Marrow Failure. Biol Blood Marrow Transplant. (1 Suppl): S12-17, Jan 2010.

35. **Sakamoto KM**, Lakoski J, and ED Fruge. Summary of ASPHO Workshop on Career Development and Increasing Diversity in Pediatric Hematology/Oncology, ASPHO Meeting in Montreal, Canada, April 2010. ASPHO newsletter, [online publication].

36. **Sakamoto KM** and G Aldana-Masangkay. MDC-3100, a small-molecule androgen antagonist, for the oral treatment of prostate cancer. Drug Profile, 2011.

37. Cho EC, Mitton B, and **KM Sakamoto**. CREB and Leukemogenesis. Critical Reviews in Leukemogenesis (Special issue of Critical Reviews in Oncogenesis; K. Sakamoto, Editor) 16: 37-46, 2011.

38. Aftandilian CC, Milotich C and **KM Sakamoto**. The neutropenic diet…still ageless? Oncology, 26:586, 2012.

39. **Sakamoto KM**. Letting miRs overcome resistance to chemotherapy in AML. Leuk Lymphoma Nov 11, 2013.

40. Rankin EB, Narla A, Park JK, Lin S, **Sakamoto KM.** Biology of the bone marrow microenvironment and myelodysplastic syndromes. Mol Genet Metab, 116:24-8, 2015.

41. **Sakamoto KM**. Lost in translation: RP and GATA1 mutations in DBA. Invited review. Blood, 239:3048-3049, 2017.

42. **Sakamoto KM**, Narla A. Perspective on Diamond-Blackfan anemia: lessons from a rare congenital bone marrow failure syndrome. Leukemia, 32:249-251, 2018.

43. Abecasis M, Cross NCP, Brito M, Ferreira I, **Sakamoto KM**, Hiyija N, Score J and RP Gale. Is Cancer Latency an outdated concept? Lessons from chronic myeloid leukemia. Leukemia July 6, 2020.

44. Smith S, Hijiya N and **KM Sakamoto**. Pediatric CML. Curr Onc Rep, 23:40, 2021.

45. Ford M, Mauro M, Aftandilian C, **Sakamoto KM***, Hijiya N*. Management of Chronic Myeloid Leukemia in Children and Young Adults. Current Hematologic Malignancy Reports (Springer), 17:121-126, 2022. ***co-senior authors** (Impact factor 4).

Book Chapters

1. Gasson JC, Baldwin GC, **Sakamoto KM**, DiPersio JF: The biology of human granulocyte-macrophage colony-stimulating factor (GM-CSF). In The Biology of Hematopoiesis, Dainiak N,

Cronkite EP, McCaffrey R, Shadduck RK (eds). John Wiley & Sons, New York, 1990, pp. 375-384.

2. Schmid I and **KM Sakamoto,** Analysis of DNA Content and Green Fluorescent Protein Expression. Current Protocols in Flow Cytometry, 7.16.1-7.16.10, 2001.

3. Rodriguez-Gonzales A and **KM Sakamoto**. Proteolysis Targeting Chimeric molecules: Recruiting Cancer-Causing Proteins for Ubiquitination and Degradation. Modulation of Protein Stability in Cancer Therapy (**Eds. KM. Sakamoto and E Rubin**), 2009.

4. Denny C and **KM Sakamoto**. Chapter on "Biology of Childhood Cancer." Principles and Practice of Pediatric Oncology, Sixth Edition, in 2010.

5. Denny C, D Wechsler, and **KM Sakamoto**. Chapter on "Biology of Childhood Cancer." Principles and Practice of Pediatric Oncology, Seventh Edition, in 2014.

6. Rankin EB and **KM Sakamoto**. "The Cellular and Molecular Mechanisms of Hematopoiesis." Bone Marrow Failure (Editors, Gary Kupfer and Gregory Reaman), 2018.

7. Kadapakkam M and **KM Sakamoto**. Pediatric Myelodysplastic Syndrome, emedicine.com, 2018.

8. Lo C, Glader B, Narla A and **KM Sakamoto**. Bone Marrow Failure. Rodak Hematology textbook 2019.

9. Eklund E, **Sakamoto K** and N. Hijiya. Biology of Chronic Myeloid Leukemia and Clinical Issues in Children and Adolescents. Rare Pediatric Hematologic Malignancies*, in press.*

10. Yu HH and **KM Sakamoto**. Redirecting the Cellular Waste Disposal Machinery to Target Transcription. Nuclear Receptors: The Art and Science of Modular Design and Discovery (Editor, Mostafa Badr), *in press.*

Books

1. Rodriguez-Gonzales A and **KM Sakamoto**. Modulation of Protein Stability in Cancer Therapy (**Eds. KM. Sakamoto and E Rubin**), 2009.

E. Special materials

1. **Sakamoto KM** and K Dipple. Becoming a Pediatric Physician-Scientist: A Woman's Perspective. Acad Med, 84:817, 2009.

2. Sakamoto K. Balancing work and life: Interview with Kathleen Sakamoto. Stem Cells 27(9): 2053-5, 2009.

3. **Sakamoto KM**, Lakoski J, and ED Fruge. Summary of ASPHO Workshop on Career Development and Increasing Diversity in Pediatric Hematology/Oncology, ASPHO Meeting in Montreal, 2010.

4. **Sakamoto KM.** Granulopoiesis vs. monopoiesis: a consequence of transcription factors dancing with the right partners. J Leuk Biol, 90: 637-638, 2011.

Digital Publications

1. Baird K and **KM Sakamoto**. Polycythemia. Manuscript (online) for Textbook in Pediatrics, emedicine.com, 2002.

2. Hagey A and **KM Sakamoto**. White Cell Disorders. Manuscript (online) for Textbook in Pediatrics, emedicine.com, 2001.

3. Buchbinder D and **KM Sakamoto**. White Cell Disorders (updated). Manuscript (online) for Textbook in Pediatrics, emedicine.com, 2005.

4. Baird K and **KM Sakamoto**. Polycythemia (updated). Manuscript (online) for Textbook in Pediatrics, emedicine.com, 2005.

5. Lasky JL, **Sakamoto KM**, Barker JL. Craniopharyngioma. Chapter in eMedicine from WebMD. Updated August 11, 2010. Available at: http://emedicine.medscape.com/article/986215-overview.

6. Lasky JL, **Sakamoto KM**, Kuznetsov D, Alsikafi NF, Cromie WJ. Gonadoblastoma. Chapter in eMedicine from WebMD. Updated August 11, 2010. Available at: http://emedicine.medscape.com/article/986581-overview.

7. Park J, Schlis K, **KM Sakamoto**. Pediatric Polycythemia. Chapter in eMedicine from WebMD. Accepted October 21, 2014. Available at: http://emedicine.medscape.com/article/957343-overview

8. Shyam R and **KM Sakamoto**. Evans Syndrome. Chapter in eMedicine from WebMD, 2018.

9. Kadapakkam M and **KM Sakamoto**. Pediatric Myelodysplastic Syndrome. Chapter in eMedicine from WebMD, 2018.

Abstracts

1. **Sakamoto K**, Raines MB, Bardeleben C, Gasson JC: GM-CSF and TPA induce a subset of primary response TIS genes in both proliferating and terminally differentiated myeloid cells. American Society of Hematology; November, 1989. Blood 74(7):73a.

2. **Sakamoto K**, Gasson JC: GM-CSF-responsive sequences upstream of the primary response gene, EGR-1/TIS8, in factor-dependent human myeloid leukemia cell lines. Blood 76(1):117a, 1990.

3. **Sakamoto K**, Gasson JC: GM-CSF-responsive sequences upstream of the primary response gene, EGR-1/TIS8, in factor-dependent human myeloid leukemia cell lines. Presented at Keystone Symposia on Molecular & Cellular Biology, "Cytokines and Their Receptors". J Cell Biochem 15F:P556, 1991.^

4. **Sakamoto K**, Rosenblatt J, Gasson JC: *Trans*-activation of the human EGR-1 promoter by the HTLV-I and -II Tax proteins in T-cell lines. Blood 78:266a, 1991.^

5. Gilliland DG, Perrin S, **Sakamoto KM**, Bunn HF: Analysis of EGR-1 and other relevant genes in patients with 5q- syndrome. Blood 78:333a, 1991.

6. **Sakamoto KM**, Lee J, Gasson JC: GM-CSF-responsive sequences upstream of the primary response gene, EGR-1/TIS8, in a human factor-dependent myeloid leukemia cell line. J Cell Biochem 16C:M234, 1992.^

7. **Sakamoto KM**, Lee JH, Gasson JC: GM-CSF and IL-3 induce EGR-1 transcriptional activation through both overlapping and distinct upstream regulatory sequences. Leukemia 6:1093, 1992.

8. **Sakamoto KM**, Lee JH-J, Gasson JC: GM-CSF and IL-3 mediate signal transduction through both overlapping and distinct upstream regulatory sequences in the human EGR-1 promoter. Blood 80:974, 1992.^

9. **Sakamoto KM**, Lee JH-J, Gasson JC: GM-CSF and IL-3 activate human early response gene (EGR-1) transcription through both overlapping and distinct upstream regulatory sequences. J Cell Biochem 17A:B974, 1993.

10. **Sakamoto KM**, Lee JH-J, Lehman ES, Gasson JC: GM-CSF and IL-3 induce early response gene expression through a novel transcription factor binding site. Blood 82:437a, 1993.^

11. Horie M, **Sakamoto KM**, Aronica S, Broxmeyer HE: Regulation of EGR-1 gene transcription by retinoic acid in a human factor-dependent cell line. Presented at the International Society of Experimental Hematology, 22:721; Minneapolis, MN; August 1994.

12. **Sakamoto KM**, Lee H-J J, Lehman ES, and Gasson JC: GM-CSF and IL-3 signal transduction in myeloid leukemic cells. Oral presentation and acceptance of the Young Investigator Award in Oncology, The American Society of Pediatric Hematology-Oncology, Chicago, IL; October 1994.^

13. **Sakamoto KM**, Lee H-J J, Lehman ES, and Gasson JC: GM-CSF and IL-3 Signal Transduction Pathways Converge on the Egr-1 and CREB-binding Sites in the Human egr-1 promoter. Presented to the American Association for Cancer Research meeting on Transcriptional Regulation of Cell Proliferation and Differentiation, Chatham, MA; October 1994.

14. Mignacca RC and **Sakamoto KM**. Transcriptional Regulation of the Human egr-1 gene by PIXY321 in a factor-dependent myeloid leukemic cell line. Presented to the American Association for Cancer Research meeting on Transcriptional Regulation of Cell Proliferation and Differentiation, Chatham, MA; October 1994.

15. Kubota H, Watanabe S, **Sakamoto K** and Arai K. Transcriptional activation of early growth response gene-1(EGR-1) by human granulocyte-macrophage colony-stimulating factor. Japanese Immunological Meetings, JAPAN; November 1994.

16. Lee H-J J, Gasson JC and **Sakamoto KM**. GM-CSF and IL-3 Activate Signalling Pathways through phosphorylation of CREB in myeloid leukemic cells. Blood 84 (10): 15a, 1994. Abstract accepted for poster presentation.

17. Mignacca RC and **Sakamoto KM**. PIXY321 responsive sequences of the human egr-1 promoter mediating proliferation in a factor-dependent myeloid leukemic cell line. Blood 84 (10): 572a, 1994.

18. Mignacca RC and **Sakamoto KM**. Transcriptional Regulation of the Human egr-1 gene by PIXY321 in a factor-dependent myeloid leukemic cell line. J. Cell. Biochem. Abstract Supp 19A A1-335, 1995. Keystone Symposia on Oncogenes, Keystone, CO; January 1995.

19. Raitano AB, Mignacca RC, **Sakamoto KM**, and Sawyers CL. Differential effects of the leukemogenic fusion proteins v-abl and bcr-abl in activation of myc and ras responsive promoter elements. J. Cell. Biochem. Abstract Supp 19A ; A1-347. Presented at Keystone Symposia on Oncogenes, Keystone, CO; January 1995.

20. H-J J Lee, JC Gasson, and **KM Sakamoto**. Granulocyte-Macrophage Colony-Stimulating Factor and Interleukin-3 Activate Signaling Pathways Through Phosphorylation of CREB in Myeloid Leukemic Cells. Western Society for Pediatric Research, Carmel, CA; February 1995.^

21. A. O'Shea-Greenfield, J. Weinstein, and **K.M. Sakamoto**. Inhibition of Granulocyte Differentiation by a Novel Cell Cycle Protein p55CDC. Abstract accepted for poster presentation, American Society of Hematology Meeting, December 1995.

22. A. O'Shea-Greenfield, J. Weinstein, and **KM Sakamoto**. Cell Cycle Regulation by a Novel Protein p55CDC. Abstract accepted for oral presentation, American Society of Hematology Meeting, December 1995.^

23. A. Wong and **KM Sakamoto**. GM-CSF Induces the Transcriptional Activation of Egr-1 Through a Protein Kinase A-Independent Signaling Pathway. Abstract accepted for poster presentation, American Society of Hematology Meeting, December 1995.

24. **KM Sakamoto.** Molecular Biology of Myeloid Growth Factors, presented as the Ross Young Investigator Award at the 1996 Western Society for Pediatric Research meeting, Carmel, February 15, 1996.^

24. A. Wong and **KM Sakamoto**. GM-CSF induces transcriptional activation of egr-1 promoter through a protein kinase A-independent signaling pathway. Oral presentation by A. Wong at the Western Society for Pediatric Research, Carmel, February 16, 1996.^

25. Kao CT, O'Shea-Greenfield A, Weinstein J, **Sakamoto KM**. Overexpression of p55Cdc accelerates apoptosis in myeloid cells. Oral presentation at the International Society of Hematology August 1996, Singapore.^

26. Lin M, Mendoza M, Weinstein J, **Sakamoto KM**. Cell Cycle Regulation by p55Cdc During Myelopoiesis. Accepted for poster presentation at the American Society of Hematology meeting, December 1996, Orlando, Fl.

27. Lin M, Weinstein, and **Sakamoto KM**. The Role of p55Cdc in Cell Proliferation. Poster presentation at the Keystone Symposia on Growth Control. Keystone, Colorado January 4, 1997.

28. Kwon EM, Lee J H-J, Wong A, and **Sakamoto, KM**. GM-CSF Signaling Pathways Lead to Activation of CREB in myeloid cells. Poster presentation at the Keystone Symposia on Hematopoiesis. Tamarron, Colorado. February, 1997.

29. Mora-Garcia P and **Sakamoto KM**. The Molecular Regulation of G-CSF Induced Myeloid Cell Proliferation and Differentiation. Poster presentation at the Keystone Symposia on Hematopoiesis, Tamarron, Colorado. February, 1997.

30. **Sakamoto KM** and Weinstein J. Increased expression of p55Cdc in myeloid cells inhibits granulocyte differentiation and accelerates apoptosis. Poster presentation at AACR, San Diego California. April, 1997.

31. Kwon EM, Raines MA and **Sakamoto KM**. GM-CSF Induces Phosphorylation of CREB Through Activation of pp90rsk in Myeloid Cells. Abstract presented at the Society for Pediatric Research by EM Kwon, April 1997.^

32. Kwon EM, Raines MA and **Sakamoto KM**. GM-CSF activates pp90RSK in Myeloid Cells Stimulated with GM-CSF. Abstract presented at the American Society of Hematology by EM Kwon, December 1997.^

33. Lin M, Weinstein, and **Sakamoto KM**. The Role of p55Cdc in Cell Proliferation. Poster presentation at the American Society of Hematology. December 1997.

*34. Wang CS, Mendoza MJ, Braun J, and **KM Sakamoto**. Differential Expression of a Novel 50kD Protein in Low- versus High-Grade Murine B-Cell Lymphomas. Abstract presented at the Western Society for Pediatric Research, Carmel. February 1998.

35. Lin M, Weinstein, and **Sakamoto KM**. The Role of p55Cdc in during G1/S Transition. Poster presentation at the Keystone Symposia on Cell Cycle, Keystone, Colorado. March 1998.

36. Wang CS, Mendoza MJ, Braun J, and **KM Sakamoto**. Differential Expression of a Novel 50kD Protein in Low- versus High-Grade Murine B-Cell Lymphomas. Poster presentation at Keystone Symposia on Cell Cycle, Keystone, Colorado. March 1998.

37.**Sakamoto, KM**. Invited participant at the Gordon Research Conference in Molecular Genetics; Newport, Rhode Island, July 1998.

38. Rolli M, Neininger A, Kotiyarov A, **Sakamoto K**, and M Gaestel. Egr-1 expression is regulated by the p38 MAP kinase Pathway Independent of MAPKAP-K2. 10th International Conference on Second messengers and Phosphoproteins, July 1998.

39.Mora-Garcia P and **Sakamoto KM**. G-CSF regulates myeloid cell proliferation through activation of SRE-binding proteins. American Society for Hematology, Miami Beach FA, 1998. Abstract accepted for poster presentation.

40. Mora-Garcia P and **KM Sakamoto**. G-CSF Regulates Myeloid Cell Proliferation Through Activation of SRE-Binding Proteins. Oral Presentation at the Western Society for Pediatrics meeting in Carmel, CA 1999.^

41. Kwon EM, Raines MA, and **KM Sakamoto**. Granulocyte Macrophage-Colony Stimulating Factor Induces cAMP response element binding protein phosphorylation through a pp90RSK activated pathway in myeloid cells. Oral Presentation at the Western Society for Pediatrics meeting in Carmel, CA 1999.^

42. Lin M, Kao C, Weinstein J, and **KM Sakamoto**. P55Cdc overexpression results in premature cell cycle transition from G1 to S phase. Oral Presentation at the Western Society for Pediatrics meeting in Carmel, CA 1999.^

43. **KM Sakamoto**. “GM-CSF Induces pp90RSK1 Activation and CREB Phosphorylation in

Myeloid Leukemic cells". NIH/NCI Workshop on "Serine/Threonine Kinases in Cytokine Signal Transduction, " Invited speaker May 30 and 31, 1999.

44. [1]H. Hsu, [2]N.G. Rainov, [1]F. Sun, [3]**K.M. Sakamoto**, and [1]M.A. Spear. 4-Ipomeanol (4-IM) prodrug activity in cells carrying the p450 CYP4B1 transgene under an EGR1 promoter induced with ionizing radiation. Am. Soc. Ther. Rad. Onc, 1999.

45. Dai W, Wu H, Lan Z, Li W, Wu S, Weinstein J, **KM Sakamoto**. BUBR1 interacts with and phosphorylates p55Cdc/hCdc20. Cold Spring Harbor Meeting, "Cell Cycle," May 2000.

46. **Sakamoto KM**, Crews C and RJ Deshaies. A novel approach to target proteins for proteolysis. Accepted for poster presentation. Keystone Symposium on Cell Cycle, Taos NM, January 2001.

47. **Sakamoto KM**, Crews C, Kumagai A, and RJ Deshaies. A novel approach to treat cancer. Accepted for poster presentation. Oncogenomics Meeting, Tucson AZ, January, 2001.

48. Deshaies RJ, **Sakamoto KM**, Seol JH, Verma R. Prospecting at the Cross-roads of ubiquitin-dependent proteolysis and cell cycle control. FASEB meeting, Orlando, FA, 2001.^

49. Crans HC, Landaw EM, Bhatia S, and **KM Sakamoto**. CREB as a prognostic marker in Acute Leukemia. Accepted for poster presentation, American Society of Hematology meeting, Orlando, FA, 2001.

50. Countouriotis A, Landaw EM, Moore TB, and **KM Sakamoto**. CREB expression in Acute Leukemia. Accepted for poster presentation and Pediatric Resident Travel Award, A. Countouriotis, Society for Pediatric Research/American Society of Pediatric Hematology/Oncology, May 2002.

51. Mora-Garcia P, Wei J, and **KM Sakamoto**. G-CSF Signaling induces Stabilization of Fli-1 protein in Myeloid Cells. American Society for Hematology, Philadelphia, PA, December 2002.

*52. Countouriotis AM, Landaw EM, Moore TB, Sakamoto KM. Comparison of bone marrow aspirates and biopsies in pediatric patients with acute lymphoblastic leukemia. Western Society for Pediatric Research, Carmel, CA. January 2003

*53. Cheng JC, Crans-Vargas HN, Moore TB, and **KM Sakamoto**. Aberrant CREB expression in Patients with Acute leukemia. Western Society for Pediatric Research. Carmel, CA. January 2003.

54. Countouriotis AM, Landaw EM, Moore TB, **KM Sakamoto**. Comparison of bone marrow aspirates and biopsies in pediatric patients with acute lymphoblastic leukemia. Society for Pediatric Research/ASPHO, Seattle, WA. January 2003.

55. Cheng JC, Crans-Vargas HN, Moore TB, and **KM Sakamoto**. Aberrant CREB expression in Patients with Acute leukemia. Western Society for Pediatric Research. Carmel, CA. January 2003. Won the SPR Resident's Research Award.

*56. Shankar DB, Cheng J, Headley V, Pan R, Countouriotis A, and **KM Sakamoto**. CREB is aberrantly expressed in acute myeloid leukemias and regulates myelopoiesis in vitro and in vivo. American Society for Hematology, San Diego, CA. December 2003.

*57. Shankar DB, Landaw EM, Rao N, Moore TB, and **KM Sakamoto**. CREB is amplified in AML blasts and is associated with an increased risk of relapse and decreased event-free survival. Oral presentation, American Society for Hematology, San Diego, CA. December 2004.

58. Shankar DB, Kinjo K, Cheng JC, Esparza S, Federman N, Moore TB, and **KM Sakamoto**. Cyclin A is a target gene of activated CREB downstream of GM-CSF signaling that regulates normal and malignant myelopoiesis. Poster presentation, American Society for Hematology, San Diego, CA. December 2004.

59. Kinjo K, Shankar DB, Cheng JC, Esparza S, Federman N, Moore TB, and **KM Sakamoto**. CREB overexpression in vivo results in increased proliferation, blast transformation, and earlier engraftment of myeloid progenitor cells. Poster presentation, American Society for Hematology, San Diego, CA. December 2004.

*60. Kinjo K, Shankar DB, Moore TB, and **KM Sakamoto**. CREB Regulates hematopoietic progenitor cell proliferation and myeloid engraftment. (AFMR Scholar Award and WSCI Travel Award Winner). WSPR, Carmel, CA, February, 2005.

*61. Menzel LP, Hummerickhouse R, Hagey A, Shah NP, Shankar DB, Moore TB, and **KM Sakamoto**. Analysis of a targeted receptor tyrosine kinase inhibitor in the treatment of acute myelogenous leukemia. WSPR, Carmel, CA, February, 2005.

*62. Shankar DB, Chang J, Parcells B, Sandoval S, Li J, Wei R, Tapang P, Davidsen SK, Albert DH, Glaser KB, Moore TB, and **KM Sakamoto**. The Multi-Targeted Receptor Tyrosine Kinase Inhibitor, ABT-869, Induces Apoptosis of AML cells both *in vitro* and *in vivo*. Accepted for an oral presentation at the American Society for Hematology, Atlanta GA, December 2005.

*63. Shankar DB, Kinjo K, Chang J, and **KM Sakamoto**. CREB Transgenic Mice Develop Myeloproliferative Disease/Myelodysplastic Syndrome after a Prolonged Latency. Accepted for an oral presentation, American Society for Hematology, Atlanta GA, December 2005.

*64. Parcells BW, Ikeda AK, Moore TB, Glaser KB, and **KM Sakamoto**. The Multi-Targeted Receptor Tyrosine Kinase Inhibitor ABT-869 Induces Apoptosis in Baf3 cells expressing the FLT3 Internal Tandem Duplication Mutation. Accepted for an oral presentation, WSPR, Carmel, CA. February 2006.

*65. Simms-Waldrip T, Hernandez J, Shankar DB, Moore TB, Shoemaker A, and **KM Sakamoto.** Targeting Bcl-2 in acute myeloid leukemia cells. Accepted for an oral presentation, WSPR Carmel, CA. February 2006.

*66. Rodriguez-Gonzalez A, Kim KB, Crews CM, Deshaies RJ, and **KM Sakamoto**. Development of Protacs to target the estrogen receptor for ubiquitination and degradation in breast cancer cells. Accepted for an oral presentation. AACR meeting, Washington DC, April 2006.

67. Francisco Martinez F, Jimenez F, Machuca C, Villegas H, and **KM Sakamoto**. Transcriptional activation of krox-1 induced by sexual hormones in osteosarcoma cells. Accepted for a poster presentation. American Society for Gene Therapy Baltimore, Maryland. May 2006.

68. Cheng JC, Shankar D, and **KM Sakamoto**. Requirement of CREB in Normal and Malignant Hematopoiesis. Accepted for poster presentation. American Society for Hematology, Orlando FL, December 2006.

69. Esparza SE, Shankar DB, and **KM Sakamoto**. Identification of Meis1 as a Target of CREB in Myeloid Leukemogenesis. Accepted for poster presentation. American Society for Hematology, Orlando FL, December 2006.

70. Sandoval S, Shankar DB, and **KM Sakamoto**. Acceleration of Leukemogenesis in CREB Transgenic mice by Retroviral Insertional Mutagenesis. American Society of Hematology, Orlando FL, December 2006.

71. Rodriguez-Gonzalez A, Ch'ng, JH, Ikeda A, Lin T, Bahrami B, Mazitschek R, Bradner JE, Fu C, and **KM Sakamoto**. Targeting Histone Deacetylase 6 and the Aggresome Pathway in Acute Lymphoblastic Leukemia Cells. Accepted for poster presentation. American Society of Hematology, Atlanta, GA, December 2007.

72. Ikeda A, Judelson D, Li J, Wei RQ, Tapang P, Davidsen SK, Albert D, Glaser KB, Fu C, and **KM Sakamoto**. Inhibiting FLT3 phosphorylation and signaling in AML. Accepted for poster presentation. American Society of Hematology, Atlanta, GA, December 2007.

73. Cheng JC, Judelson D, Kinjo K, Chang J, Landaw EM, and **KM Sakamoto**. CREB Plays a Critical Role in the Regulation of Normal and Malignant Hematopoiesis. Accepted for poster presentation. American Society of Hematology, Atlanta, GA, December 2007.

74. Hernandez J, Li J, Wei RQ, Tapang P, Davidsen SK, Albert DH, Marcotte PA., Glaser KB, Fu C, and **KM Sakamoto**. Multi-Targeted Receptor Tyrosine Kinase Inhibitor, ABT-869, Induces apoptosis and Inhibition of Proliferation of Ba/F3 FLT-3 ITD mutant cells. Accepted for poster presentation. American Society of Hematology, Atlanta, GA, December 2007.

*75. Danilova N, **Sakamoto KM**, and S Lin. Imbalance of p53 family members as a new target of therapeutics for treatment of Diamond Blackfan Anemia. Accepted for oral presentation. American Society of Hematology, Atlanta, GA, December 2007.

76. Ikeda AK, Judelson DR, Federman N, Li J, Wei RQ, Tapang P, Davidsen SK, Alber DH, Glaser KB, Landaw E, and **KM Sakamoto**. ABT-869, a Multi-targeted Receptor Tyrosine Kinase Inhibitor, Suppresses Proliferation of Ewing's Sarcoma by inhibiting the PDGFRB and c-Kit Pathways. Accepted for poster presentation. American Society of Pediatric Hematology-Oncology meeting, Cincinnati Ohio, May 2008.

77. Hernandez JE, Zape JP, Glaser KB, Fu C, and **KM Sakamoto**. Multi-targeted receptor tyrosine kinase inhibitor, ABT-869, induces apoptosis and suppresses proliferation of Ba/F3 FLT3-ITD mutant cells in vitro and in vivo through inhibition of FLT3 and AKT. American Society of Hematology meeting, San Francisco, CA, December 2008.

78. Danilova N, Morimoto K, **KM Sakamoto**, and S Lin. Aberrant p53 signaling pathways in RPL11 mutant zebrafish. American Society of Hematology meeting, San Francisco, CA, December 2008.

79. Rodriguez-Gonzalez A, Simms-Waldrip T, Ikeda A, Lin T, Ch'ng J, Travis B, Aldana-Masangkay GI, Mazitschedk R, Bradner JE, Fu C, and **KM Sakamoto**. Tubacin, an inhibitor of HDAC6, induces apoptosis of ALL cells in vitro and in vivo through a Na/K+ ATPase-dependent pathway. American Society of Hematology meeting, San Francisco, CA, December 2008.

80. Hernandez J, Zape JP, Glaser KB, Fu C, and **KM Sakamoto**. ABT-869, a multi-targeted receptor tyrosine kinase inhibitor induces apoptosis and suppresses proliferation of Ba/F3 FLT3-ITD mutant cells in vitro and in vivo through inhibition of FLT3 and AKT. Abstract accepted for poster presentation. American Association for Cancer Research, Denver, Colorado, April 2009.

81. Danilova N, **Sakamoto KM**, Lin S. Characterization of p53-dependent pathways in RPL11 mutant zebrafish. Accepted for poster presentation. American Society of Hematology, Orlando FL, December 2010.

82. Simms-Waldrip T, Cho M, Dorshkind K, and **KM Sakamoto**. CREB regulates early myelopoiesis and myeloid engraftment. Accepted for poster presentation. American Society of Hematology, Orlando FL, December 2010.

83. Mitton B, Ikeda A, Yamada, Li B, Fan Q, Landaw E, Xiao X, and **KM Sakamoto**. Inhibitor of the CREB proto-oncogene suppresses AML cell proliferation in vitro and in vivo. Accepted for poster presentation. American Society of Hematology, Orlando FL, December 2010.

*84. Manara, E, Baron E, Beghin A, Tregnago C, **Sakamoto KM**, Pigazzi M, Basso G. MiR-34b Promoter Methylation and Regulation of CREB Expression in Myeloid Transformation. Accepted for oral presentation. American Society of Hematology, Orlando FL, December 2010.

*85. Tasian SK, Doral MY, Wood BL, Collins-Underwood JR, Borowitz MJ, Harvey RC, **Sakamoto KM**, Willman CL, Hunger SP, Mullighan CG, Loh ML. Thymid Stromal Lymphopoietin Stimulation of Pediatric Acute Lymphoblastic Leukemias with CRLSF2 Alterations Inducse JAK/STAT and PI3K phosphosignaling. Accepted for oral presentation. American Society of Hematology, Orlando FL, December 2010.

86. Pigazzi M, Manara E, Bresolin S, Baron E, Beghin A, Tregnago C, TeKronnie T, **Sakamoto KM**, and G Basso. MiR-34b hypermethylation and CREB overexpression may identify MDS that evolved to AML. Accepted for Poster Presentation. European Hematology Association meeting, London, 2011.

87. Reiss U, Schwartz J, **Sakamoto KM**, Puthenveetil G, and RE Ware. Safety and Efficacy of Eculizumab in Children and Adolescents with Paroxysman Nocturnal Hemoglobinuria. Accepted for poster presentation. American Society of Hematology, San Diego, CA 2011.

88. Bibikova E, Lin S, and **KM Sakamoto**. MiR34a contributes to defective erythropoiesis in RPS19 insufficient hematopoietic stem cells. Accepted for poster presentation. American Society of Hematology, San Diego, CA 2011.

89. Aldana-Masangkay GI, Mitton B, Ikeda A, Yamada K, Li B, Fan Q, Landaw EM, Xiao X, and **KM Sakamoto**. A small molecular inhibitor targeting CREB and CBP inhibits proliferation of AML cells in vitro and in vivo. Accepted for poster presentation. American Society of Hematology, San Diego, CA 2011.

90. Danilova N, **Sakamoto KM**, and S Lin. Beneficial effects of nucleoside treatment in zebrafish models of DBA deficiency in ribosomal proteins L11 or S19. Accepted for poster presentation. American Society of Hematology, San Diego, CA 2011.

91. Chae, H-D and **KM Sakamoto**. Replication Factor C subunit 3 (RFC3) is a direct target of CREB, promotes G1/S transition of AML cells, and increases hematopoietic stem/progenitor cell self-renewal. Accepted for poster presentation. American Society of Hematology, New Orleans, LA 2013.

92. Konto-Ghiorghi Y, Bibikova E, Glader E, Narla A, and **KM Sakamoto**. Transcriptional Profiling and Cytokine Signaling in the Pathogenesis of Diamond-Blackfan Anemia. Accepted for a poster presentation. American Society of Hematology, New Orleans, LA 2013.

93. Mitton B, Dutta R, Hsu K, Xiao X, and **KM Sakamoto**. Pp90RSK-CREB signaling pathways regulate apoptosis in AML cells. Accepted for a poster presentation. American Society of Hematology, New Orleans, LA 2013.

94. Danilova N, Bibikova E, Covey TM, Nathanson D, Dimitrova E, Lindgren A, Glader B, Radu CG, **KM Sakamoto**, and S Lin. Accepted for a poster presentation. Defective nucleotide metabolism contributes to p53 activation in Diamond-Blackfan Anemia. Accepted for a poster presentation. American Society of Hematology, New Orleans, LA 2013.

95. Mitton B, Dutta R, Hsu K, and **KM Sakamoto**. The Role of pp90RSK1-mediated CREB phosphorylation in Acute Myelogenous Leukemia. Accepted for a poster presentation. American Society of Hematology, San Francisco, CA 2014.

96. Chae HD, Mitton B, and **KM Sakamoto**. CREB Regulates Cell Cycle Progression through RFC3-PCNA Axis in Acute Myeloid Leukemia. Accepted for a poster presentation. American Society of Hematology, San Francisco, CA 2014.

97. Youn MY, Bibikova E, Danilova N, Ono-Uragi Y, Konto-Ghiorghi Y, Ochoa R, Narla A, Glader B, Lin S, and **KM Sakamoto**. RPS19 Deficiency Leads to GATA1 Downregulation through TNF-mediated p38 MAPK Activation. Accepted for a poster presentation. American Society of Hematology, San Francisco, CA 2014.

98. Chae HD, Cox N, Zhang ZE, Lee JW, Morgens D, Bassik M, Smith M, and **KM Sakamoto**. The Salicylamide Derivative, Niclosamide, inhibits CREB function in Acute Myeloid Leukemia Cells In Vitro and In Vivo. Accepted for a poster presentation. American Society of Hematology, San Diego, CA 2016.

99. Wilkes M, Bibikova E, Youn MY, Narla A, Glader B, and **KM Sakamoto**. Role of miR-34 upregulation in disruption of c-Myc, c-Myb and Notch signaling in Diamond Blackfan Anemia. Accepted for a poster presentation. American Society of Hematology, San Diego, CA 2016.

100. Dutta R, Castellanos M, Chae H-D, Tiu B, Davis KL and **KM Sakamoto**. RSK Inhibition Suppresses AML Proliferation through Activation of DNA Damage Pathways and S Phase Arrest. American Society of Hematology, San Diego, CA 2016.

101. Chae HD, Dutta R, Tiu B, Davis K, Lacayo NJ and **KM Sakamoto**. RSK Inhibition induces Metaphase Arrest and Apoptosis in Acute Myeloid Leukemia Cells. Accepted for poster presentation. American Society of Hematology, Atlanta, GA 2017.

*102. Wilkes M, Lee JW, Kudaravalli S, Glader B, Narla A and **KM Sakamoto**. Nemo-like Kinase Hyper-activated in Erythroid Progenitors in Models of Diamond Blackfan Anemia. Accepted for an oral presentation. American Society of Hematology, Atlanta, GA 2017.

*103. Wilkes M, Takasaki K, Chae HD, Youn Y, Nishmura T, Lee JW, Kudaravalli S, Glader B, Repellin C, Nakauchi H, Narla A, and **KM Sakamoto**. Nemo-like Kinase is Hyperactive in RPS19-insufficient Erythroid Progenitors. 15th Diamond Blackfan Anemia International Consensus Conference, March 12, 2018.

104. Wilkes M, Takasaki K, Youn MY Chae HD, Narla A, and **KM Sakamoto**. Regulation of HSP70 by SATB1 leads to aberrant erythropoiesis in Diamond Blackfan Anemia. Beyond Transcriptomics: Understanding Erythrocyte Maturation Workshop NIDDK. Accepted for poster presentation. Bethesda, MD 2018.

*105. Wilkes MC, Chen J, Siva K, Varetti G, Dever D, Chae H, Youn MY, Narla A, Glader B, Porteus M, Repellin C, Gazda H, Serrano M, Flygare J and **KM Sakamoto**. Inhibition of Nemo-Like Kinase increases erythroid expansion in murine and human models of Diamond Blackfan Anemia. Accepted for oral presentation. American Society of Hematology, San Diego, CA 2018.

106. Wilkes M, Takasaki K, Youn MY, Chae HD, Narla A and **KM Sakamoto**. Chromatin Organization by SATB1 regulates HSP70 induction in early erythropoiesis and is lost in Diamond Blackfan Anemia. Accepted for poster presentation. American Society of Hematology, San Diego, CA 2018.

*107. Youn M, Huang H, Chen c, Kam S, Wilkes MC, Chae HD, Narla A, Lin S and **KM Sakamoto**. MMP9 Inhibition Rescues the Erythroid Defect in RPS14-deficient del(51) MDS models. Accepted for oral presentation. American Society of Hematology, San Diego, CA 2018.

108. Chae HD, Murphy LC, Donato M, Le AG, Sweet-Cordero EA, Abidi P, Bittencourt H, Lacayo N, Dahl G, Aftandilian A, Davis K, Huang M, Sumarsono N, Redell MS, Fu CH, Chen IM, Alonzo T, Eklund EA, Gotlib JR, Khatri P, Hijiya N and **KM Sakamoto**. Comparison of the Transcriptomic Signature of Pediatric vs. Adult CML. Accepted for poster presentation. American Society of Hematology, San Diego, CA 2018.

*109. Wilkes MC, Mercado J, Saxena M, Chen J, Siva K, Varetti G, Chae H, Youn MY, Gazda H, Serrano M, Flygare J and **KM Sakamoto.** Pharmacological inhibition of Nemo-like Kinase rescues mTOR-mediated translation and primes progenitors for leucine-stimulated erythroid expansion in pre-clinical models of Diamond Blackfan Anemia. Accepted for oral presentation. American Society of Hematology, Orlando, Fl, December 2019.

110. Van Hentenryck M, Thongthip S, Stone S, Hwang T, Kristovich K, Velez-Bartolomei F, Lee CU, Chu J, Narla A, **Sakamoto KM**, Glader B, Balasa V, Rao L, Agarwal R, Weinberg K, Bertaina A and A Czechowicz. Treatment Resistance in a Fanconi Anemia Mosaic Patient with Meylodysplastic Syndrome. Fanconi Anemia Research Foundation, 2020.

*111. Wilkes MC, Chae HD, Celika AM, Wentworth E, Eskin A, Chen Z, Spencely A, Nishimura T, Narla A, Glader B, Roncarolo MG, Nakauchi H, Nelson SF, Wysocka J, and **KM Sakamoto.** Novel Role for SATB1: Regulation of Megakaryocyte/Erythroid Progenitor Expansion During Hematopoiesis. Accepted for oral presentation, virtual Red Cell Club meeting, October 23, 2020.

112. Youn M, Smith SM, Chae HD, Lee AG, Murphy LC, Donato M, Sweet-Cordero A, Abidi P, Bittencourt H, Lacayo N, Dahl G, Aftandilian C, Davis K, Matthews JA, Kornblau SM, Huang M, Sumarsono N, Redell MS, Fu CH, Chen IM, Alonzo T, Eklund E, Gotlib JR, Khatri P, Hijiya N and **KM Sakamoto**. Comparison of the Transcriptomic Signatures im Pediatric and Adult CML. Accepted for poster presentation, virtual American Society of Hematology meeting, December 2020.

113. Youn M, Chae HD, Gomez O and **KM Sakamoto**. Pp90RSK Isoforms play Distinct Roles during Hematopoiesis. Accepted for poster presentation, virtual American Society of Hematology meeting, December 2020.

114. Wojciki A and **KM Sakamoto**. Genetic Modulators of Niclosamide Sensitivity and Resistance in Acute Myeloid Leukemia. Accepted for poster presentation, virtual American Society of Hematology meeting, December 2020. Received the Minority Medical Student Abstract Award.

115. Wilkes M and **KM Sakamoto**. Metformin upregulates miR-26a to improve erythropoiesis in preclinical models of Diamond Blackfan Anemia through suppression of NLK expression. Accepted for poster presentation, virtual American Society of Hematology meeting, December 2020.

116. Wilkes M and **KM Sakamoto**. SATB1 Regulates HSP70 Protein Expression in Early Hematopoiesis. Accepted for poster presentation, virtual American Society of Hematology meeting, December 2020.

117. Youn M, Chae HD, Gomez O and **KM Sakamoto**. RSK Isoforms Play Distinct Roles during Hematopoiesis. Accepted for poster presentation. Stanford Pediatric Research Retreat, April 21, 2021.

118. Jung K, Lee BE, Saxena M, Sathianathen RS, Mercado J, Perez C, Flygare J, Narla A, Glader B, **Sakamoto KM**, Wilkes MC. Ginsenoside Rb1 and Metformin improves erythropoiesis in models of Diamond Blackfan Anemia by targeting Nemo-like Kinase. ISEH meeting, accepted for poster presentation, August 2021.

119. Shibuya A, Wilkes MC, Serrano M, Flygare J, Glader B, Narla A and KM Sakamoto. Targeting Nemo-like Kinase with small molecules for potential therapy for Diamond Blackfan Anemia. Accepted for oral presentation. Maternal Child Health Research Institute Retreat, Stanford University, Stanford, CA, 2021.

120. Wilkes MC, Scanlon V, Shibuya A, Chae HD, Narla A, Glader B and KM Sakamoto. Accurate expansion of erythroid progenitors regulated by chromatin binding SATB1. Accepted for poster presentation. Maternal Child Health Research Institute Retreat, Stanford University, Stanford, CA, 2021.

121. Mark K, Robbins M, Gamble A, Bassik M, Han K and KM Sakamoto. Niclosamide Inhibits Proliferation of Leukemia Cells and Synergizes with Chemotherapy. ASH meeting, New Orleans, December, 2022.

122. Dalloul J, Powers A, Youn M, Mark K, Dror R, Wakatsuki S and KM Sakamoto. Investigation of Novel Small Molecule and Peptide Inhibitors of CREB in leukemia cells. ASH meeting, New Orleans, December, 2022.

*oral presentation of abstract

Editorial Service
Editorial board: Stem Cells, Blood, Journal of Transplantation & Stem Cell Biology, Leukemia & Lymphoma journal.

Medical Editor, emedicine online textbook for Pediatrics (Hematology-Oncology section)
Current Drugs, panel of evaluators

Other peer review activities
Ad hoc reviewer for journals: Oncogene, Proceedings of the National Academy of Sciences, Molecular and Cellular Biology, Journal of Cellular Biochemistry, Leukemia, Biotechniques, Cytometry, Pediatric Research, Cancer Research, Molecular Cancer Therapeutics, American Journal of Hematology, Molecular Genetics and Metabolism, American Journal of Human Genetics, New England Journal of Medicine, Pediatric Blood and Cancer, Cancer Research, Clinical Cancer Research, British Journal of Hematology, Clinical Prostate Cancer, Pediatrics, Cancer Letters, Journal of Pediatric Hematology-Oncology, Nature Communications, Oncotarget, Journal of Clinical Investigation, Pediatric Blood and Cancer, Chemistry and Biology, Haematologica.

Grants

Current funding

2014-2025 NIH T32DK098132 ($117,399/year). Training in Pediatric Nonmalignant Hematology and Stem Cell Biology. K. Sakamoto (P.I.).

2016-2023 NIH/NIDDK R01107286 ($250,000/year). Signaling Pathways in MDS, K. Sakamoto (P.I.). No cost extension.

2017-present Stanford Clinical and Translational Innovation grant ($200,000). Targeting CREB for AML Therapy. K. Sakamoto (P.I.)

2019-2023 Pediatric Cancer Research Foundation ($125,000). Targeted Inhibition of CREB for the Treatment of Pediatric Acute Myeloid Leukemia. K. Sakamoto, S. Wakatsuki, and R. Dror (co-P.I.s)

2019-2022 Leukemia & Lymphoma Society Translational Research Grant ($600,000). Niclosamide for the treatment of pediatric relapsed/refractory AML. K. Sakamoto (P.I.) and Norman Lacayo (co-P.I.).

2021-2023 California Institute of Regenerative Medicine ($848,098). Small molecule inhibitors of Nemo-like Kinase for Treatment of Diamond Blackfan Anemia. K. Sakamoto (P.I.).

2022-2024 Pediatric Cancer Research Foundation ($150,000). Targeting Mitochondrial Pathways in Pediatric AML. K. Sakamoto (P.I.)

2022-2024 Leukemia & Lymphoma Society Translational Research Grant (renewal) ($750,000). Niclosamide for the treatment of pediatric relapsed/refractory AML. K. Sakamoto (P.I.) and Norman Lacayo (co-P.I.).

2022-2027 R25 DK130827 ($108,000). Increasing Diversity in Hematology: Training for URM Students. K. Sakamoto and Bonnie Halpern-Felsher (co-P.I.).

Prior Funding

1989-1990 American Cancer Society Clinical Oncology Fellowship

1990-1993 5 F32 CA08974-04 Individual National Research Service Award Molecular Analysis of Target Cell Response to Human GM-CSF ($102,100); National Cancer Institute (Judith Gasson, Ph.D., P.I.)

1996-2002 Fellowship Award, Molecular Characterization of GM-CSF Action ($70,000) Leukemia Society of America (Judith C. Gasson, Ph.D., P.I.)

1993-1998 K08 CA59463, Clinical Investigator Award, Molecular Characterization of GM-CSF Action ($383,400), National Cancer Institute (Judith Gasson, Ph.D. P.I.)

1993-1996 3017-93, Special Fellow Award, Molecular Analysis of GM-CSF Action ($100,400), Leukemia Society of America (K. Sakamoto, M.D., P.I.)

1992-1995 Career Development Award, Molecular Characterization of GM-CSF Action ($150,000), STOP CANCER (K. Sakamoto, M.D., P.I.)

1992-1993 Seed Grant, Mutation Analysis of Structure-Function Relationships of Human GM-CSF Receptor Beta Subunit ($30,000), Jonsson Comprehensive Cancer Center (K. Sakamoto, M.D., P.I.)

1992-1993 Mutation Analysis of Structure-Function Relationships of the Human GM-CSF Receptor Beta Subunit ($25,000), Southern California Children's Cancer Service and Couples Against Leukemia (declined) (K. Sakamoto, M.D., P.I.)

1993-1995 Molecular Regulation of egr-1 by IL-3 and PIXY321 in Myeloid Leukemias ($100,000), Concern II (K. Sakamoto, M.D., P.I.)

1994 The Role of Cyclins in Myeloid Leukemias ($25,000), Southern California Children's Cancer Service and Couples Against Leukemia (K. Sakamoto, P.I.)

1995 UCLA Academic Senate Award ($1,500), "Stem Cell Factor Activation ofSignal Transduction in Myeloid Leukemic Cells" (K. Sakamoto, M.D., P.I.)

1995 UCLA Frontiers of Science Award, The Regulation and Functional Role of p55CDC in Myeloid Leukemias ($28,000) (K. Sakamoto, M.D., P.I.)

1995 UCLA Prime Faculty Research Award, Molecular Regulation of Myeloid Cell Differentiation ($25,000) (K. Sakamoto, M.D., P.I.)

1995 Seed Grant, The Role of SRE-Binding Proteins During Signal Transduction in Myeloid Leukemias ($27,000), Jonsson Comprehensive Cancer Center (K. Sakamoto, M.D., P.I.)

1995	New Assistant Professor Grant, Transcriptional Regulation of egr-1 by Stem Cell Factor in Myeloid Leukemias ($35,000), Cancer Research Coordinating Committee (K. Sakamoto, M.D., P.I.)
1995-1997	Shannon Award, NIH (NCI) 1R55CA68221, Molecular Regulation of Myeloid Cell Differentiation, ($80,000) (K. Sakamoto, M.D., P.I.)
1996	Concern II Foundation; Molecular Analysis of IL-3 and PIXY321 Signaling Pathways in Myeloid Leukemias ($50,000) (K. Sakamoto, M.D., P.I.)
1996-2002	First Award R29CA68221, Molecular Regulation of Myeloid Cell Differentiation, ($350,000), NIH/NCI (K. Sakamoto, M.D., P.I.)
7/97-6/99	UC Biotechnology STAR Project, S97-03 "p55Cdc and Cell Cycle Regulation" ($40,000); Amgen, Inc. and University of California (K. Sakamoto, M.D., P.I.)
7/98-6/99	Contract with Eli Lilly, Inc. "Multiple Resistance Genes in Leukemias" ($32, 000), Co-PI with Leonard Rome, Ph.D. (K. Sakamoto, M.D., P.I.)
7/98-6/99	Jonsson Comprehensive Cancer Center Seed Grant, “Use of Low Molecular Weight Heparin in Cancer Patients Receiving Stem Cell Transplants,” ($30,000), Co-P.I. with Dr. Sinisa Dovat, M.D. (fellow)
7/98-6/2003	Leukemia Society of America Scholar Award, 1497-99 "The Role of p55Cdc during Myelopoiesis" ($350,000), Leukemia Society of America (K. Sakamoto, P.I.)
1/99-12/2001	Investigator initiated grant, California Cancer Research Program, “Cell Cycle Control and Cancer” ($400,000), California Department of Health Services (K. Sakamoto, P.I.)
7/99- 6/2000	Jonsson Comprehensive Cancer Center Seed Grant, “Development of a Novel Class of Protein-inhibiting Anti-cancer Therapeutics” ($15,000), K. Sakamoto (P.I.) and Raymond Deshaies (Co-P.I., Caltech)
1/2000	CaPCURE research award, “Development of a Novel Class of Protein-Inhibiting Therapeutics for Prostate Cancer” ($100,000). Raymond Deshaies (P.I., Caltech), K. Sakamoto, and Craig Crews (Co-P.I., Yale University).
1/99-12/02	Research Project Grant, "Molecular Analysis of Myeloid Cell Proliferation" ($300,000); American Cancer Society (K. Sakamoto, P.I.)
8/01-7/03	UC Biostar, “Targeting the estrogen receptor for Proteolysis”, with Celgene, Inc. ($40,000), K Sakamoto, P.I.
1/02-12/02	CaPCURE research award, “Targeting the Androgen Receptor for Degradation in Prostate Cancer” ($75,000) K.Sakamoto (P.I.), Raymond Deshaies (Co-P.I., Caltech) and Craig Crews (Co-P.I., Yale University).

6/02-7/03 National Cancer Coalition, “Signal Transduction and Cell Cycle Analysis in Leukemia” ($5,000), K. Sakamoto (P.I.).

1/03-12/06 American Cancer Society, Research Scholar Award. “The role of CREB in Leukemogenesis,” ($625,000). K. Sakamoto (P.I.).

1/03-6/04 Department of Defense, “Targeting the estrogen receptor for ubiquitination and proteolysis in breast cancer,” ($222,819). K. Sakamoto (P.I.)

1/03-12/03 Diamond-Blackfan Anemia Foundation, “AML in Diamond-Blackfan Anemia: Molecular Basis and Therapeutic Strategies,” ($25,000). K. Sakamoto (P.I.)

1/1/03-12/31/04 SPORE grant in Prostate Cancer Research, Seed Grant Award, “Targeting the Androgen Receptor for proteolysis in Prostate Cancer,” $75,000. K. Sakamoto (P.I.)

4/1/03-3/31/04 Stein-Oppenheimer Award, “Targeting the Estrogen Receptor in Breast Cancer,” $20,000. K. Sakamoto (P.I.)

6/1/03-5/30/04 Genomic Exploration Seed Grant, Jonsson Comprehensive Cancer Center, “CREB and Human Leukemias,” $5,000, K. Sakamoto (P.I.)

7/1/03-6/30/04 Susan G. Komen Breast Cancer Thesis Dissertation Award,” $20,000. K. Sakamoto, R. J. Deshaies (P.I.)

1/04-12/08 NIH/NHLBI R01 (HL 75826), “The Role of CREB in Leukemogenesis,” ($200,000/year). K. Sakamoto (P.I.)

9/04-8/08 R21, “Ubiquitination and Degradation in Cancer Therapy,” ($135,000/year). K. Sakamoto (P.I.)

7/04-7/05 Department of Defense, “Identification of small non-peptidic ligands that bind the $SCF^{beta\text{-}TRCP}$ ubiquitin ligase to target the ER for ubiquitination and degradation ($75,000). K. Sakamoto (P.I.)

7/05-5/07 Fulbright Fellowship/MEC (Spain) postdoctoral fellowship, “Targeting the Androgen Receptor for Ubiquitination and Degradation: A new strategy for Therapy in Prostate Cancer” ($60,000), K. Sakamoto and R. Deshaies (Co-P.I.).

5/05 Boyer/Parvin Postdoctoral Fellow Award ($5,000), awarded to Deepa Shankar, Ph.D., K. Sakamoto (P.I.)

7/05 Stone Research Award ($1,000) award to undergraduate student Winston Wu, K. Sakamoto (P.I.)

7/05-6/07 Department of Defense postdoctoral fellowship, “Targeting the Androgen Receptor for Ubiquitination and Degradation: A New Strategy for Therapy in Prostate Cancer,” ($80,000), K. Sakamoto (P.I.)

10/06-9/07 Diamond Blackfan Anemia Foundation, “ Developing a zebrafish model of Diamond Blackfan Anemia.” $25,000 (K. Sakamoto and S. Lin, P.I.)

10/05-9/09	NIH/NHLBI R01 (HL083077), " Molecular and Cellular Characterization of MPD." $225,000/ year. K. Sakamoto (P.I.).
7/06-6/08	Department of Defense, "The Role of CREB in CML," $45,800/year. K. Sakamoto (P.I.)
7/06-6/08	F32 HL085013 NRSA (NHLBI), "CREB and Hematopoietic Stem Cells," awarded to postdoctoral fellow Jerry Cheng, M.D. K. Sakamoto (P.I.).
7/06-6/08	NCI T32 CA09056 Tumor Cell Biology Training Grant, "Studies in the Mechanisms of Targeted Therapy for Acute Myeloid Leukemia," for Alan K. Ikeda, M.D.,K. Sakamoto (P.I.).
10/06-9/09	Leukemia and Lymphoma Society Translational Research Grant, "Targeting Signaling Pathways in Pediatric AML." $200,000/year, K. Sakamoto (P.I.) and Ted Moore, (co-P.I.).
1/07-12/17	T32 NIH/NHLBI Training Grant, "Training in Developmental Hematology." $262,489/year, K. Sakamoto (P.I.).
1//08-12//08	Abbott Laboratories and Genentech, Inc. "RTKIs in AML." $50,000, K.Sakamoto (P.I.)
10/08-9/09	Jonsson Comprehensive Cancer Center Fellowship award, "Targeting the Aggresome Pathway in ALL." $30,000, K. Sakamoto (P.I.), Agustin Rodriguez-Gonzalez (fellow).
11/08-10/09	William Lawrence Foundation ($40,000). Targeting the Aggresome pathway in Pediatric ALL, K. Sakamoto (P.I.).
7/09-6/2010	St. Baldrick's Foundation ($50,000). The Role of p53/deltaNp63 in Oncogenesis in Bone Marrow Failure Syndromes, K. Sakamoto and S. Lin (co-P.I.).
2009	NanoPediatrics Core Seed Grant ($20,000). Identification of Molecular Targets of the CREB inhibitor XX-650-23 in Leukemia Cells, K. Sakamoto (P.I.)
2010	Parents Against Leukemia ($20,000). Genome sequencing of pediatric ALL cells. K.Sakamoto (P.I.), Stan Nelson (co-P.I.).
2010-2011	NHLBI/NCI R13 ($10,000/year). Career Development and Increasing Diversity in Pediatric Hematology/Oncology. K. Sakamoto (P.I.).
2010-2011	NIH/NHLBI. CREB and myeloproliferative disease. ARRA Supplement for Michelle Cho. K. Sakamoto (P.I.).
2011	UCLA Stein Oppenheimer Clinical Translational Seed Grant ($30,000). "Genomic analysis of Congenital ALL. K. Sakamoto and Stan Nelson (co-P.I.s).
2010-2012	ASH Alternative Training Pathway grant ($50,000). Training Pathway in Bone Marrow Failure syndromes. K. Sakamoto and G. Schiller (co-PIs).

2010-2014 NIH/NIDDK R01 HL097561 ($250,000). Molecular Pathogenesis of Diamond Blackfan Anemia. K. Sakamoto and S.Lin (co-PIs).

2009-2015 NIH/NHLBI R01 HL75826 ($250,000). The Role of CREB in normal myelopoiesis and leukemogenesis. K. Sakamoto (P.I.).

2012-2013 SPARK funding ($10,000). "Targeting CREB for leukemia therapy." K. Sakamoto (P.I.).

2013-2015 NIH R13 159800 (5,001). Career Development and Increasing Diversity in Pediatric Hematology/Oncology. K. Sakamoto (P.I.).

2010-2015 NIH R01 GM087305 ($30,000). Chemical Inhibitors of CREB mediated transcription. K. Sakamoto collaborator. X.Xiao at OHSU (P.I.).

2012-2015 Department of Defense BM110060 ($300,000). Signaling Pathways in the Pathogenesis of DBA. K. Sakamoto (P.I.).

2013-2015 Child Health Research Institute, Lucile Packard Children's Hospital at Stanford Fellowship Award to Postdoctoral Fellow, Minyoung Youn, Ph.D.K.Sakamoto (P.I.).

2013-2014 Celgene, Inc ($30,000). Effects of ACE-011 in RPS19 deficient human hematopoietic cells. $30,000. K. Sakamoto (P.I.).

2011-2014 NIH/NHLBI Minority Supplement for graduate student Grace Masangkay. Role of CREB in Myelopoiesis and Leukemogenesis, K. Sakamoto (P.I.).

2010-2014 NIH/NHLBI R01 ($250,000/year). Molecular Pathogenesis of Diamond Blackfan Anemia, K. Sakamoto (P.I.), Shuo Lin (co-P.I.).

2012-2013 NCI/NHLBI R13 ($5,000/year). Career Development and Increasing Diversity in Pediatric Hematology/Oncology. K. Sakamoto (P.I.).

2010-2014 NIH, Chemical Inhibitors of CREB mediated gene transcription ($21,000). K. Sakamoto, subcontract, Xiangshu Xiao (P.I.).

2013-2014 NHLBI/NCI R13 ($7,700/year). Career Development and Increasing Diversity in Pediatric Hematology/Oncology. K. Sakamoto (P.I.).

2013-2014 Child Health Research Institute Bridge Grant ($35,000). Genomic and Proteomic Analysis of CREB inhibition in AML cells. K. Sakamoto (P.I.).

2010-2015 NIH/NHLBI R01. The Role of CREB in Myelopoiesis and Leukemogenesis, K. Sakamoto (P.I.).

2013-2016 CureSearch Grand Challenge Grant (1.4 million dollars). Development of CD47 antibody for pediatric tumors. K. Sakamoto (P.I.) and I. Weissman (co-P.I.).

2015 SPARK ($40,000). Developing peptides to target CREB for AML therapy. K. Sakamoto/M. Smith (P.I.s).

2013-2016 SPARK program, Stanford University ($70,000). Targeting CREB for AML Therapy. K. Sakamoto (P.I.) and Mark Smith (co-P.I.).

2014-2016 Leukemia & Lymphoma Society Screen to Lead Program ($260,000). Targeting CREB for AML therapy. K. Sakamoto (P.I.).

2015-2016 Pediatric Cancer Research Foundation. Targeted Inhibition of CREB for the Treatment of Pediatric Acute Leukemias ($40,000). K. Sakamoto (P.I.).

2014-2016 Bear Necessities and Jane C. Ventura Charitable Trust ($50,000). Targeted inhibition of CREB for the treatment of AML. K. Sakamoto/Bryan Mitton (P.I.s).

2015-2016 St. Baldrick's Foundation Research Grant ($100,000). The Role of RSK1 in Acute Myeloid Leukemia. K. Sakamoto (P.I.).

2015-2016 NIH/NIDDK R56107286 ($114,000). Signaling Pathways in MDS, K. Sakamoto and Shuo Lin, co-PI.

2016 USC Parker Institute for Childhood Cancer Research/William Lawrence & Blanche Hughes Foundation ($90,000). Development of CREB inhibitors for ALL Therapy. K. Sakamoto (P.I.).

2014-2016 Acerta, Inc. Analysis of BTK and PI3Kdelta inhibitors in normal and neoplastic myeloid cells ($199,000). K. Sakamoto (P.I.).

2015-2017 Hyundai Hope on Wheels ($250,000). The Role of CREB in the Pathogenesis of Pediatric ALL and as a target for therapy. K. Sakamoto (P.I.).

2014-2018 NIH/NCI R13CA186539 ($2,500). Professional Development and Late Career Transitions in Pediatric Hematology/Oncology. K. Sakamoto (P.I.).

2018 Maternal Child Health Research Institute ($35,000). Molecular Characterization of RSK in AML, K. Sakamoto (P.I.)

2017-2019 Pediatric Cancer Research Foundation ($150,000). Targeted Inhibition of CREB for the Treatment of Pediatric Acute Myeloid Leukemia. K. Sakamoto (P.I.)

2017-2019 Bear Necessities Foundation ($200,000). CREB inhibitors for Relapsed Leukemia. K. Sakamoto (P.I.)

2018-2019 National Institutes of Health R56DK112869-01A1. The Role of the Parathyroid Hormone Receptor in Osteoblast Support of Erythropoiesis, J. Wu, P.I., K. Sakamoto (co-investigator).

2016-2020 Acerta, Inc. ($100,000). Analysis of BTK inhibitors in primary ALL cells *in vitro* and *in vivo*. K. Sakamoto (P.I.)

2018-2021 Maternal Child Health Research Institute Transdisciplinary Initiatives Program ($200,000). Small Molecules to Inhibit CREB:CBP Interaction for Treatment of Childhood Acute Leukemia. K. Sakamoto, S. Wakatsuki, R. Dror (co-investigators).

2019-2021 SPARK program ($60,000). Targeting Nemo-Like Kinase for the Treatment of Diamond Blackfan Anemia. K. Sakamoto (P.I.)

2019-2021 Diamond Blackfan Anemia Foundation ($62,000). Nemo-Like Kinase as a Target for DBA Therapy. K. Sakamoto (P.I.)

2018-2021 Hyundai Hope on Wheels ($300,000). The Role of RSK in the Pathogenesis of Pediatric AML and as a target for therapy, K. Sakamoto (P.I.)

2019-2021 Cure Childhood Cancer ($150,000). Phase I clinical trial with Niclosamide for the treatment of pediatric relapsed/refractory AML. K. Sakamoto (P.I.).

2020-2021 Cipherome, Inc. ($250,000/year). Clinical study: Pharmacodynamics in Pediatric ALL. K. Sakamoto (P.I.)

2019-2022 Department of Defense/CDMRP ($325,000). The Role of Nemo-Like Kinase in the Pathogenesis and Treatment of Diamond Blackfan Anemia. K. Sakamoto (P.I.)

2015-2025 NIH/NIDDK ($1,460,287). Training in Pediatric Nonmalignant Hematology and Stem Cell Biology. K. Sakamoto (P.I.)

2016-2023 NIH/NIDDK ($1,416,877). Signaling Pathways in MDS. K. Sakamoto (P.I.)

2019-2023 Pediatric Cancer Research Foundation ($337,500). Development of small molecules to target CREB:CBP Interaction for Treatment of AML. K. Sakamoto (P.I.)

2019-2023 Cure Childhood Cancer ($150,000). Niclosamide for the treatment of relapsed/refractory pediatric acute myeloid leukemia. K. Sakamoto (P.I.)

2019-2025 Leukemia & Lymphoma Society ($469,999; $750,000). Clinical Trial: Niclosamide for Treatment of Relapsed Pediatric Acute Myeloid Leukemia. K. Sakamoto (P.I.)

2021-2023 California Institute of Regenerative Medicine ($846,812). Small molecules to inhibit Nemo-like kinase for Treatment of Diamond Blackfan Anemia. K. Sakamoto (P.I.).

2022-2023 Pediatric Cancer Research Foundation ($150,000). Targeting Mitochondrial Pathways in Pediatric AML. K. Sakamoto (P.I.)

2022-2027 NIH/NIDDK R25 ($540,000). Increasing Diversity in Hematology: Training for URM students. K. Sakamoto (P.I.)

2023 MCHRI Pilot Grant ($35,000). Organoid Models of Pediatric Leukemia. K. Sakamoto (P.I.)

2023-2024 MCHRI TIP Grant ($200,000). Organoid Models of Pediatric Leukemia. K Sakamoto and Calvin Kuo (co-P.I.s)

2023-2024 Innovations Medicine Accelerator ($100,000). Phase I clinical trial with niclosamide for relapsed/refractory pediatric AML.

2023-2024 ASH Bridge Grant ($200,000). Investigating and Targeting the Translational Landscape of DBA. K. Sakamoto and Maria Barna (co-P.I.s)

2023-2024 NIH/NIDDK ($150,000). Investigating and Targeting the Translational Landscape of DBA. Maria Barna and K. Sakamoto (MPI)

2023-2026 CDMRP/DOD Rare Cancers Idea Development Grant ($300,000). Targeting RSK for Treatment of Pediatric AML. K. Sakamoto (P.I.)

Training faculty member on the following training grants (NIH T32 and K12 Programs)

UCLA

Tumor Cell Biology
Tumor Immunology
Hematology
Vascular Biology
Pediatric Department CHRCDA
Medical Scientist Training Program (MSTP)
Gene Medicine
Stem Cell Research Institute
Training in Developmental Hematology (P.I.)

Stanford

Cancer Biology T32CA09302
Pediatric Nonmalignant Hematology and Stem Cell Biology T32 DK098132 (P.I.)
Medical Scientist Training Program (MSTP)

Patents

"Proteolysis Targeting Chimeric Pharmaceutical" (Raymond Deshaies, Craig Crews, and Kathleen Sakamoto), Ref. No. CIT3284.

"Inhibitors of CREB:CBP Interaction for Treatment of Acute Myeloid Leukemia" (Kathleen Sakamoto, Mark Smith, Bryan Mitton, Hee-Don Chae). Ref. No. 16/081,396.

"Small molecules to target Nemo-like Kinase for treatment of bone marrow failure syndromes" (Kathleen Sakamoto, Mark Wilkes). S20-270 U.S. Provisional Application No.: 63/046,877 (STAN-1769PRV)

"Protein double-shell nano structures for guiding drug discovery" (Soichi Wakatsuki, Wah Chiu, Kaiming Zhang, Naoki Horikoshi, Kathleen Sakamoto). (STAN-S20-404).

Service as grant reviewer

1999-present	Member of Scientific Review Committee, CONCERN Foundation
2003-2007	Member, Grant Review Subcommittee on Leukemia, Immunology, and Blood Cell Development for American Cancer Society
2004	NIH Study Sections on Drug Discovery and Molecular Pharmacology and Basic Mechanisms of Cancer Therapy, and Special Emphasis Panel on Diamond-Blackfan Anemia and Bone Marrow Failure syndromes

2004	Grant Reviewer, UC Discovery Biotechnology Program
2005-2009	Member, NIH Hematopoiesis Study Section
2004	Grant Reviewer, Susan G. Komen Breast Cancer Foundation
2005-present	Member, Translation Research Program Review Subcommittee for the Leukemia and Lymphoma Society
2005-2009	Grant Reviewer, California Research Cancer Committee (CRCC)
2006	Reviewer, NIH Oncology Postdoctoral Fellowship Committee
2006-2007	CDMRP (DOD) CML Grant Review Committee
2008-present	Maryland Stem Cell Exploratory Grant Peer Review Committee
2009-2018	NY Stem Cell Grant Peer Review Committee
2008	NIH Special Emphasis Panel/CRG Loan Repayment Program Review Committee
2010-present	ASH Scholar Award Review Committee
2010	Grant reviewer, DOD new investigator awards in bone marrow failure
2010-2014	Standing member, NIH DDK-D subcommittee for training grants and K Awards.
2010	Grant reviewer, MPD Foundation
2010	Reviewer, Peggy Davison Clinician Scientist Award grant review committee
2010	Reviewer, University of Kansas Medical Center Research Institute grants
2010	Reviewer, MRC Clinician Scientist Fellowships grant committee
2010	Reviewer, National Medical Research Council grants, Singapore
2010	Reviewer, NY Stem Cell Institutional Training Review grant committee
2010	Reviewer, Children's Cancer Research Fund grant committee
2011	Ad hoc reviewer for NIH CAMP study section, R13 study section
2011	Reviewer, American Society of Hematology Research Training Award for Fellows committee
2011	Ad hoc reviewer for NIH CAMP study section
2011	Ad hoc reviewer for NIH Molecular and Cellular Hematology study section
2011	Ad hoc reviewer for NIH ZRG1 Vascular Hematology-D SEP
2011	Ad hoc reviewer for NIH R13 study section
2011	Ad hoc reviewer for NIH F30/32 study section
2011	Member, NHLBI Loan Repayment Program Review Committee
2011	Member, NCI Loan Repayment Program Review Committee
2011	Member, NCI PPG study section
2011	Member and Chair, Vascular Hematology SEP
2011	Grant reviewer, MPD Foundation grant review committee
2011-present	Grant reviewer, St. Baldrick's Foundation Scholar Award grant review committee
2011	Ad hoc member, NHLBI MPD PPG study section
2011	Ad hoc member and Chair, Vascular Hematology SEP
2011-2016	Member, NIDDK (DDK-D) study section; training grants (T32, K awards)
2012-2015	ASH Minority Medical Student Award Program
2013	NHLBI SEP grant review committee (Chair)
2013	NCI P01 grant review committee
2013	NCI SPORE grant review committee
2013	Canadian Institutes of Health Research and Terry Fox New Frontiers grant reviewer
2013	Pediatric Cancer Research Foundation Grant Review Committee
2013	UK Cancer Research Grant Review Committee
2013	Invited speaker, Swerling Symposium "Seminars in Oncology," Dana Farber Cancer Institute

2013	Jason Bennette Memorial Lectureship, Cohen Children's Hospital, Long Island, NY.
2014-2019	Member and Chair, Scientific Review Committee, Bear Necessities and Rally Foundation
2014-2018	External Advisory Committee, Four Diamonds Childhood Cancer Program, Hershey Penn State University.
2014-present	Member, Grant Review Committee, Pediatric Cancer Research Foundation
2014-present	Member, Grant Review Committee, Alex's Lemonade Stand Foundation
2016	Ad hoc reviewer for NIH BMCT, MCH and F32 study sections
2016	Reviewer for MCH SEP
2016	Reviewer, special RFA on Runx1 and Leukemia projects, Alex's Lemonade Stand Foundation.
2010-present	Member, Grant review committee, Concern Foundation
2017-present	External Advisory Committee, Hematology T32 training program, AFLAC Children's Hospital, Emory University.
2017-present	External Advisory Committee, Oncology T32 training program, Children's Hospital Los Angeles, University of Southern California.
2020-present	ASH RTAF Grant Review Committee
2021-present	Member, External Advisory Committee, Genetics T32 Training Program, Washington University
2022-present	NIDDK Council
2022-present	ASH Bridge Grant Review Committee

University Administrative Service

Committee Service - UCLA

1994	Search Committee for Director of the Jonsson Cancer Center
1995	Search Committee for Nephrology Faculty Appointment
1996-1998	Admissions Committee, UCLA ACCESS program for graduate students
1996-1999	Admissions Committee, Medical Student Training Program, UCLA
1994	UCLA Cancer Committee
2002	Search Committee for Pediatric Pulmonary
2002	Search Committee for Pediatric Nephrology
2002	Search Committee for Pediatric Hematology-Oncology
2006	Search Committee for Pediatric Cardiology
2006	Search Committee for Infectious Disease
2006	Committee for Loan Repayment, Department of Pediatrics
2006	Search Committee for Biostatistician, Department of Pediatrics
2006	Pediatric Credentials Committee
2007	Member, Coordinating Committee for CNSI-CNBI Symposium on NanoBiotechnology
2008-2010	Membership committee, CNSI-CNBI, UCLA
2008-2010	Search Committee, Pediatric Surgery
2008-2010	Quality Assurance committee, David Geffen School of Medicine
2008-2010	Admissions Policy Subcommittee, David Geffen School of Medicine
2008-2011	AMWA Mentorship Program, David Geffen School of Medicine
2009-2011	Pathology Search Committee for Faculty Position in B-ALL
2010-2011	Chair, Sherr Loan Repayment Program for Pediatric Fellows
2010-2011	Pediatric Residency Selection Committee
2011-2011	JCCC ISPRC member

Stanford

2012	Search Committee for MCL position, Clinical Director/Associate Division

	Pediatric Hematology/Oncology
2012	Search Committee for UTL position, Division of Pediatric Hematology/Oncology
2012	Search Committee for MCL position, Hematology Section, Division of Pediatric Hematology/Oncology
2012	Committee to revise Goals & Achievements form
2013	Search Committee for Pulmonary faculty
2013-present	MSTP Committee, Stanford School of Medicine
2013-present	Co-Chair of the Bass Center Tissue Bank
2014-present	School of Medicine Academic Promotions Committee, former Chair, member, and ad hoc
2017-2019	Search Committee for co-Director of Population Science, Stanford Cancer Institute
2012-2022	MCHRI Executive Committee
2017-present	Cancer Biology Graduate Student Committee
2021-present	Chair, Professional Practice Evaluation Committee
2020-present	MSTP Admissions Committee, Stanford School of Medicine
2020-present	Physician Scientist Training Program, Stanford School of Medicine
2022	Lab-based Investigator Search Committee, member
2022-present	Hepatology Section Chief Search Committee, member

Teaching

UCLA

1993-2011	Pediatric Hematology-Oncology elective
1993-2011	Advanced Clinical Clerkship in Pediatric Hematology-Oncology
1993-2011	Laboratory course in Biochemistry for first year medical students
1993-2011	Pediatric Clerkship
1993-2011	Advanced Clinical Clerkship in Pediatrics
1995	Ethics and Accountability in Biomedical Research
1995-1997	Major Concepts in Oncology
1995	Molecular and Cellular Foundations of Disease
1993-1997	Organization of Pediatric Hematology-Oncology weekly clinic conferences
1995-1999	Organization of the Pediatric Departmental Monthly Research Seminars
1999-2004	M229 Course on Cell Biology and Pathogenesis for ACCESS Graduate Students on “Cell Cycle” (organized by Patricia Johnson)
1996-2002	Pathophysiology Course in Hematopathology (session on Lymphoma)
2005	MBI 298 seminar course on Ubiquitination
2005-2010	Co-organizer, M294 Pathology course on Molecular Basis of Oncology
2009-2011	Director of M270 course on Developmental Hematology
2011	Director of UCLA Pathology M280 course

Stanford

2012-2013	Discussion leader, Hematology course for medical students
2015-present	Director, Pathology 290 course in Pediatric Nonmalignant Hematology and Stem Cell Biology
2015-present	Director, Ethics Course “Scientific Integrity,” PEDS 255

Clinical Activities

1993-2011	Medical Staff, Pediatric Hematology/Oncology, UCLA School of Medicine and Santa Monica Hospital

2011-present Medical Staff, Pediatric Hematology/Oncology, Lucile Packard School of Medicine

Leadership roles

UCLA

1994-2011 Faculty Mentor on the Medical Student Training Program
1994-2011 Principal Investigator on the Tumor Cell Biology Training Grant
1995 Faculty Advisor Program for first year medical students
1995-2011 Principal Investigator on the UCLA ACCESS program for graduate Students
2007-2009 Organize the Pediatric Fellows Core Curriculum noon seminars, Science Day
2007-2009 Organize the Basic Science Journal Clubs for Residents
2007-2011 Organize the Pediatric Translational Research Program (seed grants, grant mentors, core equipment, symposium, seminar series)
2006-2011 Organize seminars, lunch/business meetings, and roundtable discussions for the Jonsson Comprehensive Cancer Center
2007-2011 Organizer for Hematopoiesis Journal Club for Jonsson Cancer Center with Program areas in Signal Transduction, Hematologic Malignancies, and Gene Regulation

Stanford

2012-present Organize the Bone Marrow Failure Syndrome seminar series, Stanford Cancer Institute
2012-2015 Organize the Targeted therapy/Developmental therapeutics seminar series
2012-present Stanford Cancer Institute, Leadership Committee
2012-2015 Stanford Cancer Institute, Executive Committee
2014-2022 Child Health Research Institute Executive Committee
2015-present Chair, CHRI postdoctoral fellowship and research grant review committee

Service to Professional Organizations

Membership

Member, American Society of Hematology
Member, American Society of Pediatric Hematology-Oncology
Member, American Association for Cancer Research
Member, Western Society for Pediatric Research
Member, Society for Pediatric Research
Member, International Society for Experimental Hematology

Committee Service (national)

1998 Elected Council Member, Western Society for Pediatric Research
2003-present Myeloid Biology Subcommittee, Children's Oncology Group
2005-2009 Member, ASH Scientific Committee on Myeloid Biology
2006-2009 Member, Program Committee for ASPHO annual meeting
2011-2014 Member, Cancer Committee, America's Best Children's Hospital, U.S. News & World Report
2015-present CML Biology Committee, Children's Oncology Group

Leadership Roles (national)

2008	Chair of Cancer Committee, America's Best Children's Hospital, U.S. News & World Report
2010-2011	Board of Trustees, American Society of Pediatric Hematology/Oncology
2010	Vice Chair of the Myeloid Subcommittee, American Society of Hematology
2011	Chair, ASH Scientific Subcommittee on Myeloid Biology
2012-2014	Chair, of ASPHO Diversity subcommittee
2014-2016	Co-Chair of ASPHO Mid/Late Career Transition subcommittee.
2017-2022	Chair, Physician Scientist Special Interest Group Committee

Faculty mentorship (UCLA)

Faculty Mentor	Ved Longhe, Assistant Professor In-Residence
Faculty Mentor	Kek-Khee Loo, Assistant Professor In-Residence
Faculty Mentor	Tumaini Coker, Assistant Clinical Professor
Faculty Mentor	Valencia Walker, Assistant Clinical Professor

Trainees and Mentoring

High School Students

2017-2018	Sriya Kudaravalli, High School Student
2018	Simryn Kapur, High School Student, Indiannapolis, IND
2018	Mallika Saxena, High School Student, University High School
2019	Ryan Sanianathen, High School Student
2020	Aidan Gonzalez, R25/PIPs High School Student

Undergraduate students

1991-1993	Hu-Jung Julie Lee, undergraduate student
1993-present	Kathy Hwain Shin, undergraduate student, Work/study and Lab Assistant
1994-1995	Stephen Phillips, undergraduate student, Student Research Project
2003	Andy Liu, undergraduate student (Recipient of Undergraduate scholarship award for research performed in my laboratory)
2003	Ryan Stevenson, undergraduate student
2005-2006	Winston Wu, undergraduate (recipient of John Stone Award for research performed in my laboratory)
2006-2009	James Ch'ng, undergraduate student
2007-2008	Jessica Bushong, undergraduate student (recipient of CARE program award)
2008	Joan Zape, undergraduate student (Amgen Scholar Award), UC Riverside
2008	Burcu Biterge, undergraduate student, Turkey
2008-2009	Miranda Savani, UCLA undergraduate student
2012-2015	Ritika Dutta, Stanford Undergraduate student
2015-2018	Bruce Tiu, Stanford undergraduate student
2015-2017	Sharon Kam, Stanford undergraduate student
2018-2020	Ethan Wentworth, Stanford undergraduate student
2018-2021	Kevin Wang, Stanford undergraduate student
2019-2021	Omar Gomez, Stanford undergraduate student
2020-2021	Brittany Lee, Stanford undergraduate student
2022-present	Jayla Thomas, SMASH Rising URM Stanford undergraduate student
2022-present	Leonardo Daniels, SMASH Rising URM Stanford undergraduate student
2023-present	Ana Gabriela San Jose Gonzalez, Stanford undergraduate student
2023-present	Nicholas Neoman, Stanford undergraduate student
2023-present	Jacob Viduya. Community College Outreach Program student

Graduate Students

1995-2000	Evelyn Kwon, graduate student
1996-2001	Michael Lin, graduate students (recipient of NIH/NCI Tumor Cell Biology Training Grant), Dept. Pathology and Laboratory Medicine
2001-2002	Heather Crans, graduate student (recipient of NIH Tumor Immunology Training Grant), Dept. Pathology and Laboratory Medicine
2005-2010	Salemiz Sandoval, graduate student (MBI)
2005	Katrin Rhodes, rotating ACCESS graduate student
2006-2011	Jenny Hernandez, graduate student (Pathology)
2006	Andrew Goldsmith, ACCESS rotation student
2008-2015	Grace Masangkay, graduate student in Biochemistry
2008	Renee Butterworth, ACCESS graduate student (rotation)
2009	Diana Moughon, ACCESS graduate student (rotation)
2009-2013	Grace Masangkay, UCLA Chemistry and Biochemistry graduate student
2010	Maya Budzinskaya, ACCESS graduate student (rotation)
2010	Eric Gschweng, ACCESS graduate student (rotation)
2010-2014	Elena Bibikova , UCLA MBI graduate student

Medical Students

1995	Ramona Rodriguez, medical student; Short Term Training Program, Centers of Excellence
1996	Michael Mendoza, medical student, Short Term Training Program; Centersof Excellence and FIRST/STAR Award recipient
1997	Raymond Wang, medical student, Short Term Training Program
2002-2003	Tamara Greene, Medical Student, UCLA School of Medicine
2005	Cid Sumolong, STTP, UCLA medical student
2006	Sam Kaneko, first year UCLA medical student (STTP)
2006-2007	Kellie Lim, 4th year medical student mentor, UCLA Medical Specialties College Program
2008	Derek Orejel (STTP), medical student, UC Riverside/UCLA
2018	Cristina Perez, Medical Student from Michigan State University
2018	Jacqueline Mercado, Medical Student from Michigan State University
2018	Yvonne Lee, Alex's Lemonade Stand Foundation awardee and medical student, Oakland University School of Medicine, Rochester MI.
2019-2020	Anna Wojcicki, University of Minnesota School of Medicine, ASH Minority Medical Student Award Program
2022	Marilee Robbins, R35 Veterinary student

Residents

1995-1999	Wayne Chu, M.D., Pediatric Resident, Mattel Children's Hospital at UCLA, research elective (recipient of 1999 Merle Carson Lectureship, 1st Prize Southwestern Pediatric Society, The Tenth Joseph St. Geme, Jr. Research Award for UCLA Pediatric Trainees)
1999-2000	Kristin Baird, M.D. Pediatric Resident, Mattel Children's Hospital at UCLA, research elective
2001-2003	Athena Countouriotis, M.D., Pediatric Resident, Mattel Children's Hospital at UCLA, research elective (recipient of Resident Research Award, American Academy of Pediatrics)
2002-2007	Jerry Cheng, M.D., Pediatric Resident, Mattel Children's Hospital at UCLA (won SPR House Officer Award 2003, ASPHO/SPR meeting, Seattle, WA).
2003-2005	Noah Federman, M.D., Pediatric Resident, Mattel Children's Hospital,

	research elective
2007-2008	Chuck Gawad, Pediatric Resident, Mattel Children's Hospital
2007-2009	Tiffany Chang, Pediatric Resident Mattel Children's Hospital
2007	Jo Chang, Pediatric Resident, Harbor-UCLA Medical Center
2017-2018	Maria Castellano, M.D., Pediatric Resident, Lucile Packard Children's Hospital at Stanford
2018-2019	Kaoru Takasaki, M.D., Pediatric Resident, Lucile Packard Children's Hospital at Stanford

Postdoctoral Fellows, Instructors, and Junior Faculty (M.D. or Ph.D.) and current positions

1994-1995	Robert C. Mignacca, M.D., postdoctoral fellow - Dell Children's Medical Center, University of Austin.
2000-2007	Deepa Shankar, Ph.D., Postdoctoral fellow (NIH Tumor Cell Biology Postdoctoral fellowship, JCCC fellowship) – Director of Global Research and Development, Proteintech.
2002-2003	Johnny Chang, M.D., Medical Oncology Fellow, Division of Hematology-Oncology, Department of Medicine, UCLA School of Medicine (recipient Of NIH Hematology Training Grant) – Medical Oncologist, Providence Tarzana Medical Center
2005-2007	Samuel Esparza, M.D., Pediatric Hematology-Oncology fellow, STAR/PhD graduate program – Pediatric Oncology, Las Vegas.
2005-2007	Jerry Cheng, M.D., Pediatric Hematology-Oncology fellow – Director of Stem Cell Transplant, Southern California Kaiser Permanente Los Angeles
2005-2007	Tiffany Simms-Waldrip, M.D., postdoctoral fellow - Associate Professor, Division of Pediatric Hematology/Oncology, UT Southwestern School of Medicine
2006-2009	Alan Ikeda, M.D., Pediatric Hematology-Oncology fellow – Pediatric Hematologist-Oncologist, University of Nevada, Las Vegas
2006-2008	Tara Lin, M.D., Adult Oncology, Postdoctoral fellow – Associate Professor, Division of Medical Oncology, University of Kansas
2009	Kazuo Okemoto, Ph.D., postdoctoral fellow – Chief, The Japan Agency for Medical Research
2012-2014	Bryan Mitton, M.D., Ph.D., Pediatric Hematology/Oncology fellow – Pediatric Hematologist-Oncologist, Los Angeles
2013-2016	Minyoung Youn, Ph.D., postdoctoral fellow – Staff Research Scientist, Stanford University
2014	Joseph Park, M.D., Ph.D., Pediatric Hematology/Oncology fellow – Clinical Research Medical Director, Amgen
2014	Tabitha Cooney, M.D., Pediatric Hematology/Oncology fellow (co-mentor with Irv Weissman) – Assistant Professor of Pediatrics, Dana Farber Cancer Institute
2016-2020	Mark Wilkes, Ph.D., Postdoctoral Fellow – Instructor, Stanford University
2020-present	Aya Shibuya, Ph.D., postdoctoral fellow
2022-present	Hye Na Kim, Ph.D., postdoctoral fellow

Junior Faculty

2018-2020	Robbie Majzner, M.D., Instructor, Asst. Professor, Stanford University
2019-2021	Stephanie Smith, M.D., Instructor, Stanford University
2019-2021	Sneha Ramakrishnan, M.D., Instructor, Stanford University
2019-2021	Agnieszka Czechowicz, Assistant Professor, Stanford University
2020-present	Mark Wilkes, Ph.D., Instructor, Stanford University

Visiting Professors and Senior Scientist

2008-2009	Kazunari Yamada, M.D., Ph.D., Visiting Professor
2011-2020	Hee-Don Chae, Ph.D., Senior Scientist
2016-2017	Jie Zheng, M.D., Visiting Professor, Beijing Children's Hospital
2016-2017	Jae Wook Lee, M.D., Visiting Professor from Catholic University, South Korea

Ph.D. Thesis Committees for Graduate Students

UCLA

Jason Christianson(P.I. A. Rajasekkaran, Pathology) 9/10/01
Robert Clipsham (P.I. Ed McCabe, M.D., Ph.D., Genetics) 7/01
Jared Goldstine (P.I. Harry Vinters, Pathology) 3/31/04
Jennifer Woo Tufts (P.I. Arnold Berk, Molecular Biology Institute) 3/07/06
Jin Xu (P.I. Charles Sawyers, Molecular Biology Institute) 3/04
Robert Signer (P.I. Ken Dorshkind, Pathology) 3/17/06
Alexandria Young (P.I. Debora Farber, Ph.D., Ophthalmology) 4/26/06
Katrin Rhodes (P.I. Hanna Mikkola, Ph.D., MCDB) 2009
Gustavo Gomez (P.I. Shuo Lin, Ph.D., MCDB) 2010
Amy Cook (P.I. Ravi Bhatia, M.D., City of Hope), 2010
Jeanette Grant (P.I. Steve Dubinett, M.D.) 2012
Jen Chun (P.I. Mike Teitell, M.D., Ph.D.), Ph.D., 2014

Stanford

Gerald Tiu (MSTP, P.I. Maria Barna, Ph.D.), graduated 2019
Amira Barkal (MSTP, P.I. Irv Weissman, M.D.), graduated 2019
Gunsagar Gulati (MSTP, P.I. Irv Weissman, M.D.), graduated 2019

Presentations

A. Local, Regional, and National

1. " Cytokine Signals and Cell Cycle Control During Myelopoiesis" Childhood Leukemia, Biological and Therapeutic Advances. April 17, 1998, Los Angeles, California.

2. Serine/Threonine Phosphorylation in Cytokine Signaling Workshop sponsored by the National Cancer Institute. March 30, 1999, Washington, D.C.

3. "Signal Transduction Pathways Activated by GM-CSF." October 29-30, 1999. ACS Professors Meeting, New York.

4. "Signal Transduction and Cell Cycle Control in Myeloid Cells" for Meet-the-Experts Breakfast, American Society of Hematology, December 5, 1999, New Orleans, LA.

5. CapCURE meeting, September 2000, Lake Tahoe. "Novel Approach to treat Prostate Cancer"

6. ITP, Olive View Grand Rounds, 8/01

7. Childhood Leukemia: causes and treatment. American Cancer Society, Los Angeles Chapter, 10/01

8. “The Role of SCF Ubiquitin Ligase in Human Disease: Implications for Therapy.” Caltech Biolunch, March 6, 2002.

9. “Development of Approaches to Target Proteins for Ubiquitination and Degradation in Human Disease.” Thesis Defense, Caltech. December 18, 2003.

10. “The Role of CREB in Leukemogenesis,” Pediatric Research Seminar, May 20, 2004.

11. “Targeting the Ubiquitin-Proteasome System for Cancer Therapy.” Minisymposium on Modulation of Protein Stability, AACR, Anaheim, CA, April 20, 2005.

12. “The Role of CREB in Myelopoiesis.” Myeloid Workshop, Annapolis, MD, 2005

13. “The Use of RNA Interference to Study and Treat Human Disease.” Organizer, Cell Biology Methods workshop, PAS/SPR meeting, Washington, D.C., 2005.

14. Young Investigators Workshop. American Society of Pediatric Hematology-Oncology meeting, Washington D.C. 2005.

15. “Update on Acute Leukemia: Where we’ve been and where we are today.” Pediatric Grand Rounds, Children’s Hospital of Los Angeles. August 19, 2005.

16. “Successes and Challenges of Childhood Cancer: Leukemia as a Model.” Life after Childhood Cancer, March 29, UCLA symposium sponsored by the Leukemia and Lymphoma Society of America.

17. “Update on Childhood Leukemia.” Pediatric Grand Rounds, Charles R. Drew University of Medicine and Science, April 4, 2006.

18. “Choosing a Career in Basic Science Research.” Young Investigator Workshop (organizer). ASPHO/SPR meeting. April 30, 2006.

19. “RNA interference and Stem Cells,” New Approaches in Stem Cell Technologies Workshop, SPR meeting, San Francisco, California. April 29, 2006.

20. “ Update on Childhood Leukemias.” Olive View Grand Rounds, May 17, 2006.

21. “Molecular and Cellular Characterization of MPD: The Role of CREB in Myelopoiesis.” NIH/NHLBI grantees meeting on MPD and MDS, November 9, 2006.

23. “Promotions: Rising up the Academic Ladder.” Young Investigator’s Workshop, ASPHO meeting, May 2007.

24. “Childhood Leukemia.” Harbor-UCLA Pediatric Grand Rounds, May 24, 2007.

25. “Update on Childhood Leukemia.” Cedars-Sinai Hematology-Oncology Grand Rounds, August 14, 2007.

26. “New therapies for acute leukemia.” Leukemia and Lymphoma Society of America fund raiser, Parents Against Leukemia, Woodland Hills, October 27, 2007.

27. “Molecular Characterization of CREB in MPD.” NHLBI Grantees meeting, November 6, 2007.

51. “Molecular pathogenesis and Targeted therapies in leukemia,” Pediatric Hematology-Oncology, NCI, November 8, 2007.

28. “CREB downregulation in normal and neoplastic hematopoietic cells.” Invited speaker, Gene Therapy Symposium, Nappa Valley, November 15, 2007.

29. PCRF symposium: 25 years of Cancer Research, “Molecular Mechanisms of AML and targeted therapies.” Invited speaker, Anaheim, California. January 11, 2008.

30. University of Wisconsin Frontiers in Pharmacology, “Molecular Mechanisms of Leukemogenesis and Targeted Therapies.” Invited speaker, March 25, 2008. Madison, Wisconsin.

31. AACR Roundtable Session on “Careers in Clinical and Translational Cancer Research.” San Diego, April 12, 2008.

32. AACR Session Chair for Minisymposium on “Gene Regulation in Cancer,” AACR meeting. San Diego, April 14, 2008.

33. “Molecular Mechanisms of Leukemogenesis and Targeted Therapies.’ Cincinnati Children’s Hospital, May 12, 2008.

34. “How to write your first NIH grant.” Young Investigator’s Workshop, American Society of Pediatric Hematology-Oncology annual meeting, Cincinnati Ohio. May 15, 2008.

35. Sakamoto KM and Joanne Hilden. “Ethics and Writing.” Young Investigator’s Workshop, American Society of Pediatric Hematology-Oncology annual meeting, Cincinnati Ohio. May 15, 2008.

36. Sakamoto KM and Jeff Lipton. “Translational Research: how not to fall between the bench and the bedside”. American Society of Pediatric Hematology-Oncology annual meeting, Cincinnati Ohio. May 17, 2008.

37. “ Mechanisms of Leukemogenesis and Targeted Therapies”. City of Hope seminar, September 17, 2008.

38. “Molecular Regulation of MPD.” NIH MPD grantees meeting, Bethesda, Maryland. November 14, 2008.

39. “The Role of GM-CSF and CREB in myeloid proliferation and survival” Speaker and Chair of Myeloid Biology Subcommittee Session. American Society of Hematology Meeting, San Francisco, CA. December 2008

40. “Myelodysplastic disease in children” Simi Valley Hospital, January 22, 2009.

41. “Signaling pathways downstream of RPS19 and RPL11 deficiency in zebrafish and hematopoietic cells.” DBA ICC Meeting, New York City, NY. March 14, 2009.

42. “Alternative models of DBA.” Session Chair, Ribosome-based diseases. American Society of Pediatric Hematology/Oncology. San Diego, California. April 26, 2009.

43. “CREB regulates normal hematopoiesis and contributes to development of AML.” NIH Myeloid Stem Cell meeting, Annapolis, Maryland. Mary 10, 2009.

44. “Ubiquitin and Ubiquitin-like Modifiers for Cancer Therapy.” American Society of Clinical Oncology. Orlando, Florida. June 2, 2009.

45. “Disorders of Ribosome Biogenesis” ASBMT Meeting, Orlando, Florida. February 24, 2010.

46. “Career Development and Increasing Diversity in Pediatric Hematology/Oncology” Introduction and Organizer, ASPHO meeting, Montreal, Canada, April 10, 2010.

47. “Translational Research in Pediatric Hematology/Oncology.” UT Southwestern June 15, 2010.

48. “Translational Research in Normal and Aberrant Hematopoiesis,” Stanford University, July 7, 2010.

49. “The Role of CREB in Myeloid Leukemogenesis,” Speaker and Chair of Session on Myeloid Leukemia, American Society of Pediatric Hematology/Oncology Annual Meeting, Baltimore Maryland, April 15, 2011.

50. “CREB and Myeloid Neoplasms.” FASEB meeting in Saxton Rivers, Vermont, August 5, 2011.

51. “REDE: Recruitment to Expand Diversity and Excellence.” Division faculty meeting, April 9, 2012.

52. “Targeting the ubiquitin-proteasome pathway for cancer therapy.” Research seminar, Oakland Children’s Hospital, April 11, 2012.

52. “Pediatric Cancer: Genome to Targeted Therapies.” Changing Lives, Creating Legacies Event. Stanford LPCH Foundation, June 5, 2012.

53. “Personalized Medicine and Targeted Therapies for Pediatric Cancer.” Stanford LPCH Board Retreat, June 6, 2012.

54. “CREB Inhibitors to treat Acute Leukemia.” Stanford SPARK program presentation, June 6, 2012.

55. “Congenital Disorders of Bone Marrow Failure – Pathophysiology and Laboratory Diagnostic Advances. American Society for Clinical Laboratory Science, Los Angeles, CA. July 20, 2012.

56. “Molecular Characterization of Normal and Aberrant Hematopoiesis.” Division of Pediatric Hematology/Oncology Monthly Research Seminar, August 10, 2012.

57. “Molecular Regulation of normal and aberrant myelopoieis” Cancer Biology students, October 31, 2012 Stanford University.

58. “Pediatric Cancer: Genome to Targeted Therapies” for Lucile Packard Foundation, November 28, 2012.

59. “CREB Inhibitors to Treat AML” SPARK program presentation for grant funding, December 3, 2012.

60. “Targeting CREB in myelopoiesis” Susan Swerling Lectures, Dana Farber Cancer Institute, May 14, 2013, Boston, MA.

61. “Signaling Pathways and Targeting CREB in Acute Myeloid Leukemia.” Research Seminar, Indiana University, October 10, 2013, Indianapolis, IND.

62. “Targeting CREB for AML Therapy.” SPARK presentation, Stanford University, December 16, 2013.

63. “Target Product Profile: Targeting CREB in Acute Myeloid Leukemia.” SPARK meeting TPP presentation, February 12, 2014.

64. “Targeting CREB for AML Therapy.” SICB networking dinner for medical students, Stanford University, Institute for Chemical Biology, March 13, 2014.

65. “Signaling Pathways and Targeting CREB for Acute Myeloid Leukemia.” Texas Children’s Cancer Center, November 13, 2014.

66. Lab journal club, Sakamoto lab. January 8, 2015.

67. “Targeting CREB in AML” presentation for SPARK visitors from Indiana University, January 21, 2015.

68. “ALL Disease and Treatment Update.” Presentation for Leukemia and Lymphoma Society, July 9, 2015.

69. “Grant Writing: Introduction,” LPCH/Stanford Pediatric Hematology/Oncology Grand Rounds, September 17, 2015.

70. “Molecular Characterization of Pediatric CML,” Children’s Oncology Group Meeting, Dallas,TX, October 8, 2015.

71. “Mock Study Section,” Trainee workshop, American Society of Hematology, Orlando, FL. December 4, 2015.

72. “Targeting the Histone Acetyltransferase CBP and CREB for Cancer Therapy,” Cancer Biology Training Grant Seminar, December 9, 2015.

73. “Response to Critiques,” Grants Workshop for Pediatric Hematology/Oncology fellows. January 7, 2015.

74. “Targeting CREB for AML Therapy,” Leukemia SPORE presentation, National Cancer Institute. April 8, 2016.

75. “Methods, Manners, and Responsible Conduct of Research,” Ethics Course for T32, June 22, 2016.

76. “Preparing a Successful Mentored Career Grant Application,” ASPHO meeting, Minneapolis, MN, May, 2016.

77. “ Adapting to the Changing Landscape of Pediatric Hematology/Oncology and Preparing for the Future,” ASPHO meeting, Minneapolis, MN, May 2016.

77. “Early Career Roundtable Luncheon,” ASPHO Meeting, Minneapolis, MN, May 2016.

78. “Targeting CREB for Cancer Therapy,” Bio-X student seminar, Stanford University, August 17, 2016.

79. “Grant Writing 101: Introduction to Grants,” Pediatric Hematology/Oncology Grand Rounds, Stanford University, September 1, 2016.

80. “Update on the Biology and Treatment of Acute Myeloid Leukemia,” Pediatric Cancer Research Foundation Memorial Lectureship, November 4, 2016.

81. Ask the Expert Panel, Leukemia & Lymphoma Society Childhood Cancer Symposium, Levi Stadium, Santa Clara, CA, March 10.

81. “CREB as a Target for AML Therapy,” Leukemia Research Group, June 1, 2018.

82. “Targeted Therapies for AML” MD Anderson Pediatric Grand Rounds, June 25, 2018.

83. “Grant Writing 101,” Pediatric Hematology/Oncology Grand Rounds, Stanford University, August 2019.

84 “ Signaling Pathways in the Pathogenesis and Treatment of Pediatric Leukemia,” Pediatric Hematology/Oncology Grand Rounds, Stanford University, November 2019.

85. “Signaling Pathways in Bone marrow failure syndromes,” Yale University, 2020 (postponed due to COVID, until 2021).

86. “Signaling Pathways in normal and aberrant hematopoiesis,” Cancer Biology Retreat, 2020.

87. Sakamoto lab research, Bio-X Undergraduate Student Research Program lecture, 2020.

88. “Signaling Pathways in the Pathogenesis and Treatment of Pediatric AML,” Cancer Biology Journal Club for graduate students, October 21, 2020.

89. “Targeting Nemo-like Kinase for Treatment of Diamond Blackfan Anemia,” SPARK meeting, November 11, 2020.

90. “Introduction to Grant Writing,” Pediatric Hematology/Oncology Grand Rounds, November 19, 2020.

91. “CREB Inhibitors for Treatment of AML,” AACR Industry Roundtable on Precision Medicine and Real World Evidence, December 1, 2020.

92. ASPHO Physician Scientist Special Interest Group, “Introduction to Grant Writing,” ASPHO meeting, May 22. 2021.

93. “Signaling Pathways in the Pathogenesis and Treatment of Pediatric AML,” McGill University CHHD noon seminar, May 17, 2021.

94. “Transient Aberrant Myelopoiesis,” Stanford University, Division of Neonatology M and M conference, June 21, 2021.

95. “Activated PI3K delta syndrome,” Leukemia and Lymphoma Conference, October 19, 2021.

96. “Wellness Workshop: Diversity,” American Society of Pediatric Hematology/Oncology, May, 2022.

97. “Models and Signaling Pathways in Diamond Blackfan Anemia,” Pediatric Hematology/Oncology Grand Rounds, February, 2023.

98. “Pediatric CML,” Fellows Teaching Conference, September 22, 2022
.
99. “Pediatric CML SOP”, Leukemia and Lymphoma Programmatic Meeting. 2023.

100. “JMML,” Fellow’s Teaching Conference, April 14, 2023.

101. “Introduction to Hematopoiesis,” R25 Hematology Lecture Series, June 26, 2023.

102. “Keys to Success for Basic Scientists,” U2C/TL1 Orientation Meeting, July 10, 2023.

B. International Meetings

1. “Targeting Proteins for ubiquitination and degradation for cancer therapy.” Invited speaker, AACR-NCI-EORTC meeting, Geneva, Switzerland, October 22, 2008.

2. “Targeting the Histone Acetyltransferase CBP and CREB for Cancer Therapy,” FASEB meeting on Histone Deacetylases and Sirtuins in Biology, Disease, and Aging. Invited Speaker, Hamburg, Germany, August 20, 2015.

C. Visiting Professorships

1. “Mechanisms of leukemogenesis and targeted therapies.” Fernbach Distinguished Lectureship. Texas Children’s Hospital, Houston Texas. April 2, 2009.

2. “Targeting the Ubiquitin-Proteasome system for Cancer Therapy,” Brent Ely Visiting Professor lectureship, April 7, 2011.

3. “Clinical Features and Molecular Pathogenesis of Bone Marrow Failure Syndromes.” Pediatric Grand Rounds, Brent Ely Visiting Professorship, April 8, 2011.

4. “Signaling pathways in normal and aberrant hematopoiesis” Jason Bennette Memorial Lectureship. Cohen Children’s Hospital, September 16, 2013, Long Island, NY.

5. “The Role of CREB in Myeloid Leukemogenesis and as a Target for Therapy,” Steve Rosen Lecture, Lurie Cancer Center, Northwestern University School of Medicine, April 16, 2015.

XI. Community Service

2007-2008 Leukemia and Lymphoma Society of America, Los Angeles Chapter, Board of Trustees and Executive Board.

2020 – Leukemia and Lymphoma Society of America, Palo Alto. March, 2020.